<SEC-DOCUMENT>0001437749-25-008989.txt : 20250324
<SEC-HEADER>0001437749-25-008989.hdr.sgml : 20250324
<ACCEPTANCE-DATETIME>20250324165019
ACCESSION NUMBER:		0001437749-25-008989
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		7
FILED AS OF DATE:		20250324
DATE AS OF CHANGE:		20250324

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Clene Inc.
		CENTRAL INDEX KEY:			0001822791
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				852828339
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-286058
		FILM NUMBER:		25764802

	BUSINESS ADDRESS:	
		STREET 1:		6550 SOUTH MILLROCK DRIVE, SUITE G50
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84121
		BUSINESS PHONE:		801-676-9695

	MAIL ADDRESS:	
		STREET 1:		6550 SOUTH MILLROCK DRIVE, SUITE G50
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Chelsea Worldwide Inc.
		DATE OF NAME CHANGE:	20200827
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>clnn20240815_s3.htm
<DESCRIPTION>FORM S-3
<TEXT>
<html><head>
	<title>clnn20240815_s3.htm</title>
	<!-- Generated by ThunderDome Portal - 3/24/2025 8:09:22 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt 0pt 6pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; text-indent: 0pt;"><b>As filed with the Securities and Exchange Commission on&nbsp;<a data-tblloc="1x1" data-tblname="618880" data-tblv="16" id="led618880F202410201732137313415">March 24, 2025</a></b></p>

<p style="margin: 6pt 0pt 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; text-indent: 0pt;"><b>Registration No. 333-</b></p>

<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0">
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; font-variant: normal; margin: 0pt; text-align: center;"><b>UNITED STATES</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; font-variant: normal; text-align: center; margin: 0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 6pt; text-indent: 0pt;"><b>WASHINGTON, D.C. 20549</b></p>

<hr class="hr-custom" style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 20%; border: none; margin: 0pt auto 0pt auto;">
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 16pt; font-variant: normal; text-align: center; margin: 6pt 0pt 3pt; text-indent: 0pt;"><b>FORM S-3</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt; text-indent: 0pt;"><b>REGISTRATION STATEMENT</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt; text-indent: 0pt;"><b>UNDER</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 6pt; text-indent: 0pt;"><b>THE SECURITIES ACT OF 1933</b></p>

<hr class="hr-custom" style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 20%; border: none; margin: 0pt auto 0pt auto;">
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 22pt; font-variant: normal; text-align: center; margin: 6pt 0pt 3pt; text-indent: 0pt;"><b>CLENE INC.</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 3pt 0pt 6pt; text-align: center; text-indent: 0pt;">(Exact name of registrant as specified in its charter)</p>

<hr class="hr-custom" style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 20%; border: none; margin: 0pt auto 0pt auto;">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Delaware</b></p>
			</td>
			<td style="vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>85-2828339</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">(State or Other Jurisdiction</p>
			</td>
			<td style="vertical-align: top; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">(I.R.S. Employer</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">of Incorporation or Organization)</p>
			</td>
			<td style="vertical-align: top; width: 10%; font-size: 8pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">Identification Number)</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 6pt;">&nbsp;</p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;"><b>6550 South Millrock Drive, Suite G50</b></p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;"><b>Salt Lake City, Utah 84121</b></p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;"><b>Tel: (801) 676-9695</b></p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 8pt; text-align: center;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 6pt;">&nbsp;</p>

<hr class="hr-custom" style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 20%; border: none; margin: 0pt auto 0pt auto;">
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 6pt 0pt 0pt; text-align: center; text-indent: 0pt;"><b>Robert Etherington</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>President and Chief Executive Officer</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>6550 South Millrock Drive, Suite G50</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center; text-indent: 0pt;"><b>Salt Lake City, Utah 84121</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 3pt; text-align: center; text-indent: 0pt;"><b>Tel: (801) 676-9695</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 3pt 0pt 6pt; text-align: center; text-indent: 0pt;">(Name, address, including zip code, and telephone number, including area code, of agent for service)</p>

<hr class="hr-custom" style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 20%; border: none; margin: 0pt auto 0pt auto;">
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 6pt 0pt; text-align: center; text-indent: 0pt;"><b>Copies to:</b></p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Jerry Miraglia, Esq.</b></p>
			</td>
			<td style="vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Tom McAleavey</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>General Counsel and Corporate Secretary</b></p>
			</td>
			<td style="vertical-align: top; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Holland &amp; Knight LLP</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>500 Principio Parkway West, Suite 400</b></p>
			</td>
			<td style="vertical-align: top; width: 10%; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>200 South Orange Avenue, Suite 2600</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 45%; font-size: 10pt; text-align: center;"><b>North East, Maryland 21901</b></td>
			<td style="vertical-align: top; width: 10%; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 45%; font-size: 10pt; text-align: center;"><b>Orlando, Florida 32801</b></td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Tel: (443) 273-1645</b></p>
			</td>
			<td style="vertical-align: top; width: 10%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Tel: (407) 244-5108</b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 6pt;">&nbsp;</p>

<hr class="hr-custom" style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 20%; border: none; margin: 0pt auto 0pt auto;">
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 6pt 0pt; text-indent: 0pt; text-align: justify;"><b>Approximate date of commencement of proposed sale to the public:</b> From time to time after this Registration Statement becomes effective.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 6pt 0pt; text-indent: 0pt; text-align: justify;">If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box:&nbsp;&#9744;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 6pt 0pt; text-indent: 0pt; text-align: justify;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box:&nbsp;&#9746;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 6pt 0pt; text-indent: 0pt; text-align: justify;">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&#9744;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 6pt 0pt; text-indent: 0pt; text-align: justify;">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&#9744;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 6pt 0pt; text-indent: 0pt; text-align: justify;">If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. &#9744;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 6pt 0pt; text-indent: 0pt; text-align: justify;">If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box.&nbsp;&#9744;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 6pt 0pt; text-indent: 0pt; text-align: justify;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of&nbsp;&#8220;large accelerated filer,&#8221;&nbsp;&#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and&nbsp;&#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr style="font-size: 9pt;">
			<td style="width: 25%; font-size: 8pt;">Large accelerated filer</td>
			<td style="width: 25%; font-size: 8pt;">&#9744;</td>
			<td style="width: 25%; font-size: 8pt;">Accelerated filer</td>
			<td style="width: 25%; font-size: 8pt;">&#9744;</td>
		</tr>
		<tr style="font-size: 9pt;">
			<td style="font-size: 8pt;">Non-accelerated filer</td>
			<td style="font-size: 8pt;">&#9746;</td>
			<td style="font-size: 8pt;">Smaller reporting company</td>
			<td style="font-size: 8pt;">&#9746;</td>
		</tr>
		<tr style="font-size: 9pt;">
			<td style="font-size: 8pt;">&nbsp;</td>
			<td style="font-size: 8pt;">&nbsp;</td>
			<td style="font-size: 8pt;">Emerging growth company</td>
			<td style="font-size: 8pt;">&#9744;</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 6pt 0pt; text-indent: 0pt; text-align: justify;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.&nbsp;&#9744;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 6pt 0pt; text-indent: 0pt; text-align: justify;"><b>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.</b></p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><font style="color:#ff0000">The information contained herein is not complete and may be changed. These securities may not be sold nor may offers to buy be accepted prior to the time the Registration Statement becomes effective. This prospectus shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale is not permitted.</font></b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><font style="color:#ff0000"><b>SUBJECT TO COMPLETION, DATED&nbsp;<a data-tblloc="1x2" data-tblname="618880" data-tblv="16" id="led618880F202410201732137345599">MARCH 24, 2025</a></b></font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b>PROSPECTUS</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 18pt; margin: 0pt; text-align: center;"><b><a data-tblloc="2x1" data-tblname="618883" data-tblv="16" id="led618883F202410201732137851704">$160,000,000</a></b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><img alt="clenelogo11percent.jpg" src="clenelogo11percent.jpg"></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 26pt; margin: 0pt; text-align: center;"><b>Clene Inc.</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 16pt; margin: 0pt; text-align: center;"><b>Common Stock</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 16pt; margin: 0pt; text-align: center;"><b>Preferred Stock</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 16pt; margin: 0pt; text-align: center;"><b>Debt Securities</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 16pt; margin: 0pt; text-align: center;"><b>Warrants</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 16pt; margin: 0pt; text-align: center;"><b>Units</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">From time to time, we may offer and sell up to&nbsp;<a data-tblloc="2x1" data-tblname="618883" data-tblv="16" id="led618883F202410201732137859063">$160,000,000</a>&nbsp;aggregate dollar amount of our common stock, preferred stock, debt securities, warrants to purchase our common stock, preferred stock or debt securities, and/or units consisting of some or all of these securities, in any combination, together or separately, in one or more offerings, in amounts, at prices and on the terms that will be determined at the time of the offering and which will be set forth in a prospectus supplement. The prospectus supplement may also add, update or change information contained in this prospectus.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">The securities may be sold directly to investors, through agents designated from time to time or to or through underwriters or dealers, on a continuous or delayed basis. If any agents, underwriters or dealers are involved in the sale of any securities with respect to which this prospectus is being delivered, the names of such agents, underwriters or dealers and any applicable fees, commissions, discounts and over-allotment options will be set forth in a prospectus supplement.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">You should read this prospectus and any prospectus supplement or amendment carefully before you invest in our securities. This prospectus may not be used to consummate sales of these securities unless it is accompanied by a prospectus supplement.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">Our common stock and public warrants are listed on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the symbols &#8220;CLNN&#8221; and &#8220;CLNNW,&#8221; respectively. On <a data-tblloc="2x1" data-tblname="618880" data-tblv="16" id="led618880F202410201732137357904">March 21, 2025</a>, the last reported sale price of our common stock and public warrants on Nasdaq was&nbsp;<a data-tblloc="3x1" data-tblname="618880" data-tblv="16" id="led618880F202410201732137382486">$4.14</a>&nbsp;and <a data-tblloc="4x1" data-tblname="618880" data-tblv="16" id="led618880F202410201732137390275">$0.0317</a>, respectively.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">As of&nbsp;<a data-tblloc="2x1" data-tblname="618880" data-tblv="16" id="led618880F202410201732137357904">March 21, 2025</a>, the aggregate market value of our common stock held by our non-affiliates, as calculated pursuant to the rules of the SEC, was approximately $36.4&nbsp;million, based upon 7,376,524&nbsp;shares of our outstanding common stock held by non-affiliates at the per share price of&nbsp;$4.94, the closing sale price of our common stock on Nasdaq on&nbsp;January 24, 2025 which is within 60 days of the date of this prospectus. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in a public offering with a value exceeding more than one-third of our &#8220;public float&#8221; (i.e., the market value of our common stock held by our non-affiliates) in any 12-month period so long as our public float remains below $75.0 million. We have sold $8.8&nbsp;million of securities in reliance on General Instruction I.B.6 of Form S-3 during the 12 calendar months prior to and including the date of this prospectus.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;"><b>Investing in our securities involves a high degree of risk. See &#8220;Risk Factors&#8221; section on page&nbsp;<a class="tocPGNUM" href="#P1RISKFACTORS" style="color:unset;text-decoration:unset;">9</a> of this prospectus and other risk factors contained in any applicable prospectus supplement and in the documents incorporated by reference herein and therein.</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">We are a&nbsp;&#8220;smaller reporting company,&#8221; as that term is defined under the federal securities laws and, as such, we have elected to comply with certain reduced public company reporting requirements and may elect to do so in future filings.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;"><b>Neither the SEC nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt; text-align: center;"><b>The date of this prospectus is&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; , 2025.</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 21pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><a id="P1TOC" name="P1_TOC" title="P1_TOC"></a>TABLE OF CONTENTS</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 92%; font-size: 8pt;">&nbsp;</td>
			<td style="width: 8%; border-bottom: 1px solid rgb(0, 0, 0); text-align: center; font-size: 8pt;"><b>Page</b></td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 92%;"><a href="#P1ABOUTPROSPECTUS" style="-sec-extract:exhibit;">ABOUT THIS PROSPECTUS</a></td>
			<td style="width: 8%; text-align: center;"><a class="tocPGNUM" href="#P1ABOUTPROSPECTUS" style="color:unset;text-decoration:unset;">1</a></td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 92%;"><a href="#P1CAUTIONARYNOTE" style="-sec-extract:exhibit;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></td>
			<td style="width: 8%; text-align: center;"><a class="tocPGNUM" href="#P1CAUTIONARYNOTE" style="color:unset;text-decoration:unset;">2</a></td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 92%;"><a href="#P1MARKETDATA" style="-sec-extract:exhibit;">MARKET AND INDUSTRY DATA</a></td>
			<td style="width: 8%; text-align: center;"><a class="tocPGNUM" href="#P1MARKETDATA" style="color:unset;text-decoration:unset;">4</a></td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 92%;"><a href="#P1SUMMARY" style="-sec-extract:exhibit;">PROSPECTUS SUMMARY</a></td>
			<td style="width: 8%; text-align: center;"><a class="tocPGNUM" href="#P1SUMMARY" style="color:unset;text-decoration:unset;">5</a></td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 92%;"><a href="#P1RISKFACTORS" style="-sec-extract:exhibit;">RISK FACTORS</a></td>
			<td style="width: 8%; text-align: center;"><a class="tocPGNUM" href="#P1RISKFACTORS" style="color:unset;text-decoration:unset;">9</a></td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 92%;"><a href="#P1PROCEEDS" style="-sec-extract:exhibit;">USE OF PROCEEDS</a></td>
			<td style="width: 8%; text-align: center;"><a class="tocPGNUM" href="#P1PROCEEDS" style="color:unset;text-decoration:unset;">10</a></td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 92%;"><a href="#P1CAPITALSTOCK" style="-sec-extract:exhibit;">DESCRIPTION OF CAPITAL STOCK</a></td>
			<td style="width: 8%; text-align: center;"><a class="tocPGNUM" href="#P1CAPITALSTOCK" style="color:unset;text-decoration:unset;">11</a></td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 92%;"><a href="#P1DEBT" style="-sec-extract:exhibit;">DESCRIPTION OF DEBT SECURITIES</a></td>
			<td style="width: 8%; text-align: center;"><a class="tocPGNUM" href="#P1DEBT" style="color:unset;text-decoration:unset;">16</a></td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 92%;"><a href="#P1WARRANTS" style="-sec-extract:exhibit;">DESCRIPTION OF WARRANTS</a></td>
			<td style="width: 8%; text-align: center;"><a class="tocPGNUM" href="#P1WARRANTS" style="color:unset;text-decoration:unset;">23</a></td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 92%;"><a href="#P1UNITS" style="-sec-extract:exhibit;">DESCRIPTION OF UNITS</a></td>
			<td style="width: 8%; text-align: center;"><a class="tocPGNUM" href="#P1UNITS" style="color:unset;text-decoration:unset;">24</a></td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 92%;"><a href="#P1DISTRIBUTION" style="-sec-extract:exhibit;">PLAN OF DISTRIBUTION</a></td>
			<td style="width: 8%; text-align: center;"><a class="tocPGNUM" href="#P1DISTRIBUTION" style="color:unset;text-decoration:unset;">25</a></td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 92%;"><a href="#P1LEGAL" style="-sec-extract:exhibit;">LEGAL MATTERS</a></td>
			<td style="width: 8%; text-align: center;"><a class="tocPGNUM" href="#P1LEGAL" style="color:unset;text-decoration:unset;">27</a></td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 92%;"><a href="#P1EXPERTS" style="-sec-extract:exhibit;">EXPERTS</a></td>
			<td style="width: 8%; text-align: center;"><a class="tocPGNUM" href="#P1EXPERTS" style="color:unset;text-decoration:unset;">27</a></td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 92%;"><a href="#P1MOREINFO" style="-sec-extract:exhibit;">WHERE YOU CAN FIND MORE INFORMATION</a></td>
			<td style="width: 8%; text-align: center;"><a class="tocPGNUM" href="#P1MOREINFO" style="color:unset;text-decoration:unset;">27</a></td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 92%;"><a href="#P1INCORPORATED" style="-sec-extract:exhibit;">INFORMATION INCORPORATED BY REFERENCE</a></td>
			<td style="width: 8%; text-align: center;"><a class="tocPGNUM" href="#P1INCORPORATED" style="color:unset;text-decoration:unset;">28</a></td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="i" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">i</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: justify;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><a id="P1ABOUTPROSPECTUS" name="P1_ABOUTPROSPECTUS" title="P1_ABOUTPROSPECTUS"></a>ABOUT THIS PROSPECTUS</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">This prospectus is part of a Registration Statement on Form S-3 (the &#8220;Registration Statement&#8221;) that we filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) using the &#8220;shelf&#8221; registration process. Under this shelf registration process, we may offer and sell shares of our common stock, preferred stock, debt securities, warrants to purchase our common stock, preferred stock or debt securities, and/or units, either individually or in combination with other securities, in one or more offerings, up to a total dollar amount of <a data-tblloc="2x1" data-tblname="618883" data-tblv="16" id="led618883F202410201732137865601">$160,000,000</a>.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">This prospectus provides you with a general description of the securities we may offer. Each time we offer securities under this prospectus, we will provide a prospectus supplement that will contain more specific information about the terms of that offering. The prospectus supplement may also add information to, or update or change information contained in, this prospectus. You should read both this prospectus and any applicable prospectus supplement or post-effective amendment to the Registration Statement, together with the additional information to which we refer you in the section of this prospectus entitled &#8220;Where You Can Find More Information,&#8221; and together with the information incorporated by reference as described in the section of this prospectus entitled &#8220;Information Incorporated By Reference.&#8221;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">You should rely only on the information incorporated by reference or set forth in this prospectus or the applicable prospectus supplement. We have not authorized anyone to provide you with any information or to make any representations other than those contained in this prospectus, or any applicable prospectus supplement or post-effective amendment to the Registration Statement. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We will not make an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus is accurate only as of the date on the front cover of this prospectus. Our business, financial condition, results of operations and prospects may have changed since that date.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">For investors outside of the United States: We have not done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of securities and the distribution of this prospectus outside of the United States.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">We urge you to read carefully this prospectus, before deciding whether to invest in the securities being offered.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described under &#8220;Where You Can Find More Information.&#8221;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;"><b>We use various trademarks and trade names in our business, including without limitation our corporate name and logo. All other trademarks or trade names referred to in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus may be referred to without the &#174; and &#8482; symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.</b></p>

<div contenteditable="false" data-applyto="t" data-auto-pgnum="start" data-displaynum="1" data-fontname="'Times New Roman', Times, serif" data-fontsize="10pt" data-numstyle="a" data-pgnumtype="auto" data-prefix="" data-startnum="1" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="1" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><a id="P1CAUTIONARYNOTE" name="P1_CAUTIONARYNOTE" title="P1_CAUTIONARYNOTE"></a>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 21pt;">This prospectus, any prospectus supplement and the other documents we have filed with the SEC that are incorporated by reference herein contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Our forward-looking statements include, but are not limited to, statements regarding our or our management team&#8217;s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this prospectus may include, for example, statements about:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our future financial performance, including our ability to continue as a going concern;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our plans and strategies to raise additional funding;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the clinical results of our drug candidates;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the likelihood of commercial success for our drug candidates;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our plans and strategies&nbsp;to obtain and maintain regulatory approvals of our drug candidates;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the size and growth potential of the markets for our drug candidates, and our ability to serve those markets, either alone or in combination with others;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">changes in the market for our drug candidates;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">expansion plans and opportunities; and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">other factors detailed under &#8220;Risk Factors&#8221; in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 21pt;">These forward-looking statements represent our views as of the date of this prospectus and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 21pt;">As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our substantial dependence on the successful commercialization of our drug candidates, if approved, in the future;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our inability to maintain the listing of our common stock on Nasdaq;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our significant net losses and net operating cash outflows;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our ability to demonstrate the efficacy and safety of our drug candidates;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the clinical results for our drug candidates, which may not support further development or marketing approval;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our ability to achieve commercial success for our drug candidates, if approved;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our ability to obtain and maintain protection of intellectual property for our technology and drug candidates;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our reliance on third parties to conduct research, drug development, and other services;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our limited operating history and our ability to obtain additional funding for operations and to complete the licensing or development and commercialization of our drug candidates;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the impact of epidemics, pandemics, and the ongoing conflicts between Ukraine and Russia and Israel and Hamas on our clinical development, commercialization, and other operations;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">changes in applicable laws or regulations;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the effects of inflation;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the effects of staffing and materials shortages;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the possibility that we may be adversely affected by other economic, business, and/or competitive factors; and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">other risks and uncertainties set forth in &#8220;Risk Factors&#8221; in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 21pt;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to rely unduly upon these statements.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><a id="P1MARKETDATA" name="P1_MARKETDATA" title="P1_MARKETDATA"></a>MARKET AND INDUSTRY DATA</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 21pt;">We obtained the industry and market data used throughout this prospectus from our own internal estimates and research, as well as from independent market research, industry and general publications and surveys, governmental agencies, publicly available information and research, surveys, and studies by third parties. Internal estimates are derived from publicly available information released by industry analysts and third-party sources, our internal research&nbsp;and our industry experience, and are based on assumptions made by us based on such data and our knowledge of our industry and market, which we believe to be reasonable. In some cases, we do not expressly refer to the sources from which this data is derived. In addition, while we believe the industry and market data included in this prospectus is reliable and based on reasonable assumptions, such data involve material risks and other uncertainties and are subject to change based on various factors, including those discussed in &#8220;Risk Factors.&#8221; These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties or by us.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><a id="P1SUMMARY" name="P1_SUMMARY" title="P1_SUMMARY"></a>PROSPECTUS SUMMARY</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;"><i>This summary highlights selected information from this prospectus and does not contain all of the information that is important to you in making an investment decision. This summary is qualified in its entirety by the more detailed information included elsewhere in this prospectus. Before making your investment decision with respect to our securities, you should carefully read this entire prospectus and the information incorporated herein by reference. Unless the context otherwise requires, references to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;the Company,&#8221; &#8220;Clene&#8221; and similar designations are intended to mean the business and operations of Clene Inc. and its consolidated subsidiaries.</i></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 0pt;"><b>Overview</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">We are a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (&#8220;CSN<sup style="vertical-align:top;line-height:120%;">&#174;</sup>&#8221;) therapeutics. CSN<sup style="vertical-align:top;line-height:120%;">&#174;</sup> therapeutics are comprised of atoms of transition elements that, when assembled in nanocrystal form, possess unusually high, unique catalytic activities not present in those same elements in bulk form. These catalytic activities drive, support, and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed, and damaged cells.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">Our patent-protected, proprietary position affords us the potential to develop a broad and deep pipeline of novel CSN therapeutics to address a range of diseases with high impact on human health. We innovated an electro-crystal-chemistry drug development platform that draws from advances in nanotechnology, plasma and quantum physics, material science, and biochemistry. Our platform process results in nanocrystals with faceted structures and surfaces that are free of the chemical surface modifications that accompany other production methods. Many traditional methods of nanoparticle synthesis involve the unavoidable deposition of potentially toxic organic residues and stabilizing surfactants on the particle surfaces. Synthesizing stable nanocrystals that are both nontoxic and highly catalytic has overcome this significant hurdle in harnessing transition metal catalytic activity for therapeutic use. Our clean-surfaced nanocrystals exhibit catalytic activities many-fold higher than other commercially available nanoparticles, produced using various techniques, that we have comparatively evaluated.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">Our development and clinical efforts are dedicated to revolutionizing the treatment of neurodegenerative diseases to restore and protect neuronal health and function. Our nanotherapeutics target cellular energy impairments that are common to many diseases and we are currently focused on addressing the high unmet medical needs in central nervous system disorders including amyotrophic lateral sclerosis (&#8220;ALS&#8221;), multiple sclerosis (&#8220;MS&#8221;), and Parkinson&#8217;s disease (&#8220;PD&#8221;). We currently have no drugs approved for commercial sale and have not generated any revenue from drug sales. We have never been profitable and have incurred operating losses in each year since inception. We generate revenue from sales of dietary supplements through our wholly owned subsidiary, dOrbital, Inc., or through an exclusive license with 4Life Research LLC (&#8220;4Life&#8221;), an international supplier of health supplements, stockholder, and related party. We anticipate these revenues to be small compared to our operating expenses and to the revenue we expect to generate from potential future sales of our drug candidates, for which we are currently conducting clinical trials.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 0pt;"><i><b>Recent Developments of Our Clinical Programs</b></i></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 0pt;"><i>Amyotrophic Lateral Sclerosis</i></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">In December 2024, we announced that we recently received written guidance from the Division of Neurology 1 (&#8220;DN1&#8221;) of the U.S. Food and Drug Administration (&#8220;FDA&#8221;) regarding a potential accelerated approval pathway for CNM-Au8 in ALS. As announced previously in September 2024, we were initially advised that the data presented in our briefing package for CNM-Au8 was not adequate to support an NDA submission under the accelerated approval pathway. However, following our November 2024 meeting with DN1 and presentation of additional data and analyses, the FDA provided guidance on a potential path to meet the regulatory standard for substantial evidence of effectiveness supporting accelerated approval. The FDA recommended that we investigate whether additional data from our ongoing compassionate use Expanded Access Programs (&#8220;EAPs&#8221;) could be leveraged to substantiate the effect of CNM-Au8 on neurofilament light (&#8220;NfL&#8221;) decline. We intend to follow the FDA&#8217;s recommendation to provide data from the ongoing EAPs and believe we can address the FDA&#8217;s requests. The additional NfL biomarker collection and analyses to support NDA submission is planned to be completed during the third quarter of 2025, as summarized below:</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>NfL biomarker analyses</i>&#8212;Provide supportive evidence of NfL declines in participants from our ongoing FDA-authorized compassionate-use EAPs. We will meet with the FDA in the first half of 2025 to review and finalize our statistical analysis plan for the EAP NfL biomarker analyses.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Survival pharmacometric modeling</i>&#8212;Provide analyses of NfL and related disease-specific biomarkers linked to clinical survival benefit and clinical changes from the Phase 2 trial data.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Additional ALS-specific biomarkers</i>&#8212;Provide analyses of additional ALS-disease specific biomarkers to support the pharmacodynamic activity of CNM-Au8 for treatment of ALS.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">The FDA noted that whether NfL can serve as a reasonably likely surrogate endpoint for the effects of CNM-Au8 in ALS and whether the magnitude of change observed on NfL in patients treated with CNM-Au8 is reasonably likely to predict clinical benefit for ALS would be a matter of review.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">In preparation for an NDA submission in the second half of 2025 with the accelerated approval request, we plan to commence a confirmatory Phase 3 trial, RESTORE-ALS, with participant enrollment beginning prior to the submission of the NDA. The trial is designed to investigate the effects of CNM-Au8 on improved survival (primary endpoint) and delayed time to ALS clinical worsening events (secondary efficacy endpoint). We have submitted the RESTORE-ALS trial protocol to the FDA and the FDA review process is ongoing.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">In March 2025, we announced evidence from a cross-regimen, <i>post hoc</i> analysis comparing survival in participants who received CNM-Au8 30 mg (Regimen C) to those of Regimen A in the HEALEY ALS Platform Trial. Regimen A provided a large concurrent control group versus CNM-Au8 treatment using the same randomization criteria established within the HEALEY master protocol. Long-term survival status, determined through public records and site reporting, was evaluated over a follow-up period of up to 48 months. 78% of participants across both groups received standard ALS background therapy (riluzole, edaravone, or both) at baseline. Overall survival improvement (all-cause mortality) was observed across the full analysis set as follows:</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Median Survival</i>&#8212;CNM-Au8 30 mg group (Regimen C, n=59) achieved 951 days versus 753 days in the Regimen A comparator group (n=162), a gain of 198 days (6.5 months);</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Restricted Mean Survival Time (&#8220;RMST&#8221;) Benefit</i>&#8212;covariate-adjusted RMST improvement of 124 days (4.1 months) was observed (95% CI: 3 to 245 days, p=0.045). RMST is a metric that estimates the average time a group survives relative to a comparator. The estimate incorporated the prespecified covariates for survival analyses from the HEALEY ALS Platform Trial (i.e., months from symptom onset, pre-treatment ALSFRS-R slope, age, background riluzole treatment, background edaravone treatment); and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Sensitivity analyses, which included additional covariate models such as baseline serum NfL levels, use of ALS background therapy, and the TRICALS risk score, confirmed the robustness and statistical significance of the findings.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">An enhanced benefit in moderate to severe ALS was observed including:</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In participants with baseline serum NfL &gt; 33 pg/mL and TRICALS risk score range between &#8211;6.5 and &#8211;2.5 (i.e., filtering slow progressors where there was an imbalance between groups), median survival improved from 589 days (Regimen A, n=120) to 951 days (CNM-Au8 30 mg, n=51), representing an 11.9 month gain; and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Mortality risk in this group decreased by 44% (Cox HR: 0.556, 95% CI: 0.367&#8211;0.842, p=0.006) with an RMST improvement of 197 days (6.5 month gain; 95% CI: 65 to 329 days, p=0.004), when using the prespecified covariates for survival analyses from the HEALEY ALS Platform Trial.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">The strongest survival benefit was observed in a participant subset who met the planned Phase 3 RESTORE-ALS trial enrollment criteria:</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Among participants who met the core RESTORE-ALS trial criteria (e.g., baseline serum NfL &gt; 33 pg/mL, TRICALS risk score range between &#8211;6.5 and &#8211;2.5, baseline slow vital capacity &gt; 60%, and symptom onset &lt; 36 months), median survival improved from 628 days (Regimen A, n=94) to 1079 days (CNM-Au8 30 mg, n=40), an increase of 451 days (14.8 months); and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">This subset experienced a 49% reduction in mortality risk (Cox HR: 0.514, 95% CI: 0.319&#8211;0.830, p=0.006) and an RMST improvement of 215 days (7.1 months; 95% CI: 70 to 360 days, p=0.004), when using the planned covariates for the RESTORE-ALS trial.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 0pt;"><i>Multiple Sclerosis</i></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">We have initiated a second dosing cohort of REPAIR-MS, an open-label, investigator blinded Phase 2 clinical trial in non-active progressive MS patients. Enrollment concluded in January 2025 with topline results expected during the second half of 2025. We plan to work closely with regulatory health authorities from the FDA, European Medicines Agency and other international regulatory bodies, MS experts, and patient representatives to determine the proper path to advance CNM-Au8 into Phase 3 and potential future approval. We expect to meet with the FDA in an end of Phase 2 meeting in the second half of 2025.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">The chart below reflects the growing body of evidence for CSN therapeutics from our completed and ongoing clinical programs.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<div style="text-align: center;">
<div><img alt="pipelinejan2025_22pct.jpg" src="pipelinejan2025_22pct.jpg"></div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b style="font-size: 10pt; text-align: justify; text-indent: 0pt;">Going Concern</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">We incurred a loss from operations&nbsp;<a data-tblloc="3x3" data-tblname="618881" data-tblv="16" id="led618881F202410201732138531920" originalfact="$33,093,000" scale-include-commas="true" scale-precision="1" scale-round="true" scale-show-unit="true" scale-unit="1000000">$33.1 million</a>&nbsp;and&nbsp;<a data-tblloc="3x4" data-tblname="618881" data-tblv="16" id="led618881F202410201732138539040" originalfact="$40,540,000" scale-include-commas="true" scale-precision="1" scale-round="true" scale-show-unit="true" scale-unit="1000000">$40.5 million</a>&nbsp;for the <a data-tblloc="1x3" data-tblname="618881" data-tblv="16" id="led618881F2025261741302074059">years ended December 31,</a>&nbsp;<a data-tblloc="2x3" data-tblname="618881" data-tblv="16" id="led618881F202410201732138546409">2024</a>&nbsp;and <a data-tblloc="2x4" data-tblname="618881" data-tblv="16" id="led618881F202410201732138553004">2023</a>, respectively. Our accumulated deficit was&nbsp;<a data-tblloc="7x1" data-tblname="618881" data-tblv="16" id="led618881F202410201732138561372" originalfact="$282,123,000" scale-include-commas="true" scale-precision="1" scale-round="true" scale-show-unit="true" scale-unit="1000000">$282.1 million</a>&nbsp;and&nbsp;<a data-tblloc="7x2" data-tblname="618881" data-tblv="16" id="led618881F202410201732138570005" originalfact="$242,723,000" scale-include-commas="true" scale-precision="1" scale-round="true" scale-show-unit="true" scale-unit="1000000">$242.7 million</a>&nbsp;as of <a data-tblloc="6x1" data-tblname="618881" data-tblv="16" id="led618881F202410201732138578574">December 31, 2024</a>&nbsp;and <a data-tblloc="6x2" data-tblname="618881" data-tblv="16" id="led618881F202410201732138585758">December 31, 2023</a>, respectively. Our cash, cash equivalents, and marketable securities totaled&nbsp;<a data-tblloc="10x1" data-tblname="618881" data-tblv="16" id="led618881F202410201732138593465" originalfact="$12,155,000" scale-include-commas="true" scale-precision="1" scale-round="true" scale-show-unit="true" scale-unit="1000000">$12.2 million</a>&nbsp;and&nbsp;<a data-tblloc="10x2" data-tblname="618881" data-tblv="16" id="led618881F202410201732138601252" originalfact="$35,000,000" scale-include-commas="true" scale-precision="1" scale-round="true" scale-show-unit="true" scale-unit="1000000">$35.0 million</a>&nbsp;as of <a data-tblloc="6x1" data-tblname="618881" data-tblv="16" id="led618881F202410201732138607242">December 31, 2024</a>&nbsp;and <a data-tblloc="6x2" data-tblname="618881" data-tblv="16" id="led618881F202410201732138614115">December 31, 2023</a>, respectively, and net cash used in operating activities was&nbsp;<a data-tblloc="4x3" data-tblname="618881" data-tblv="16" id="led618881F202410201732138625324" originalfact="$21,326,000" scale-include-commas="true" scale-precision="1" scale-round="true" scale-show-unit="true" scale-unit="1000000">$21.3 million</a>&nbsp;and&nbsp;<a data-tblloc="4x4" data-tblname="618881" data-tblv="16" id="led618881F202410201732138631445" originalfact="$30,171,000" scale-include-commas="true" scale-precision="1" scale-round="true" scale-show-unit="true" scale-unit="1000000">$30.2 million</a>&nbsp;for the <a data-tblloc="1x3" data-tblname="618881" data-tblv="16" id="led618881F2025261741302092284">years ended December 31,</a>&nbsp;<a data-tblloc="2x3" data-tblname="618881" data-tblv="16" id="led618881F202410201732138646766">2024</a> and <a data-tblloc="2x4" data-tblname="618881" data-tblv="16" id="led618881F202410201732138652543">2023</a>, respectively.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">We have incurred significant losses and negative cash flows from operations since our inception. We have not generated significant revenues since our inception, and we do not anticipate generating significant revenues unless we successfully complete development and obtain regulatory approval for commercialization of a drug candidate. We expect to incur additional losses in the future, particularly as we advance the development of our clinical-stage drug candidates, continue research and development of our preclinical drug candidates, and initiate additional clinical trials of, and seek regulatory approval for, these and other future drug candidates. We expect that within the next twelve months, we will not have sufficient cash and other resources on hand to sustain our current operations or meet our obligations as they become due unless we obtain additional financing. Additionally, pursuant to our senior secured convertible promissory notes (the &#8220;2024 SSCP Notes&#8221;), we are required to maintain unrestricted cash and cash equivalents of at least $2.0 million to avoid acceleration of the full balance of the 2024 SSCP Notes. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="7" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">To mitigate our funding needs, we plan to raise additional funding, including exploring equity financing and offerings, debt financing, licensing or collaboration arrangements with third parties, as well as utilizing our existing at-the-market facility and equity purchase agreement and potential proceeds from the exercise of outstanding warrants and stock options. These plans are subject to market conditions and reliance on third parties, and there is no assurance that effective implementation of our plans will result in the necessary funding to continue current operations. During the year ended December 31, 2024, we generated $2.7 million of gross proceeds from our equity distribution agreement (the &#8220;ATM Agreement&#8221;), raised $3.5 million from a registered direct offering of equity securities and an additional $3.8 million from separate, concurrent private placements of equity securities, and raised $10.0 million from the issuance of the 2024 SSCP Notes of which $7.9 million was used to repay the remaining balance of our obligations under a term loan with Avenue Venture Opportunities Fund, L.P. (&#8220;Avenue&#8221;).&nbsp;Additionally, subsequent to December 31, 2024, we generated $2.5&nbsp;million of gross proceeds from our ATM Agreement. We have implemented cost-saving initiatives, including delaying and reducing certain research and development programs and commercialization efforts and elimination of certain staff positions. We have concluded that our plans do not alleviate the substantial doubt about our ability to continue as a going concern beyond one year from the date the consolidated financial statements are issued.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">The accompanying consolidated financial statements have been prepared assuming we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As a result, the accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets and their carrying amounts, or the amounts and classification of liabilities that may result should we be unable to continue as a going concern.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 0pt;"><b>Smaller Reporting Company Status</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">We are a &#8220;smaller reporting company&#8221; because the market value of our stock held by non-affiliates was less than $250 million as of June 30, 2024. We may continue to be a smaller reporting company in any given year if either (i) the market value of our stock held by non-affiliates is less than $250 million as of June 30 in the most recently completed fiscal year or (ii) our annual revenue is less than $100 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700 million as of June 30 in the most recently completed fiscal year. As a smaller reporting company, we are eligible for and may take advantage of certain exemptions from various reporting requirements applicable to other public companies for as long as we continue to be a smaller reporting company, including (i) the choice of presenting only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K, (ii) the exemption from the auditor attestation requirements with respect to internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act, and (iii) reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 0pt;"><b>Corporate History and Information</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">Clene Nanomedicine, Inc. (&#8220;Clene Nanomedicine&#8221;) became a public company on December 30, 2020 (the &#8220;Closing Date&#8221;) when it completed a reverse recapitalization (the &#8220;Reverse Recapitalization&#8221;) with Tottenham Acquisition I Limited (&#8220;Tottenham&#8221;), and with Tottenham&#8217;s wholly-owned subsidiary and our predecessor, Chelsea Worldwide Inc., and Creative Worldwide Inc., a wholly-owned subsidiary of Chelsea Worldwide Inc. On the Closing Date, Chelsea Worldwide Inc. changed its name to Clene Inc. and listed its shares of common stock, par value&nbsp;<a data-tblloc="25x2" data-tblname="618876" data-tblv="16" id="led618876F202410201732138349570">$0.0001</a>&nbsp;per share (&#8220;common stock&#8221;), on Nasdaq under the symbol &#8220;CLNN.&#8221;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">We effected a 1-for-20 reverse stock split of our common stock beginning with the opening of trading on July 11, 2024 (the &#8220;Reverse Stock Split&#8221;). As a result, every 20 shares of common stock issued and outstanding were automatically combined and converted into 1 validly issued, fully paid and non-assessable share. All outstanding stock options, warrants, rights to restricted stock awards, convertible debt, and contingent earn-out shares entitling their holders to purchase or receive shares of common stock were adjusted as a result of the Reverse Stock Split, in accordance with the terms of each such security. In addition, the number of shares reserved for issuance pursuant to our Amended 2020 Stock Plan was also appropriately adjusted. All historical share and per share data for the periods presented in this prospectus, including for periods ending prior to July 11, 2024, has been adjusted to reflect the 1-for-20 Reverse Stock Split.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">The mailing address for our principal executive office is 6550 South Millrock Drive, Suite G50, Salt Lake City, Utah 84121, and our telephone number is (801) 676-9695. Our website address is <i>https://clene.com</i>. The information contained in or accessible from our website is not incorporated into this prospectus, and you should not consider it part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 0pt;"><b>The Offering</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">Under&nbsp;this prospectus, we may offer and sell to the public in one or more series or issuances of common stock, preferred stock, debt securities, warrants to purchase our common stock, preferred stock or debt securities, and/or units consisting of some or all of these securities with an aggregate offering price not to exceed <a data-tblloc="2x1" data-tblname="618883" data-tblv="16" id="led618883F2025061736202233952">$160,000,000</a>.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="8" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><a id="P1RISKFACTORS" name="P1_RISKFACTORS" title="P1_RISKFACTORS"></a>RISK FACTORS</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;"><i>Investing in our securities involves a high degree of risk. Before deciding whether to invest in our securities, you should carefully consider the risks and uncertainties described under &#8220;Risk Factors&#8221; in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, which are incorporated herein by reference, together with the information contained in this prospectus and any other information that has been or will be incorporated herein by reference. The occurrence of one or more of the events or circumstances described in these risk factors, alone or in combination with other events or circumstances, may have a material adverse effect on our business, reputation, revenue, financial condition, results of operations and future prospects, in which event the market price of our common stock could decline, and you could lose part or all of your investment. The risk factors are not intended to be exhaustive and are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations. This prospectus also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially and adversely from those anticipated in the forward-looking statements as a result of a number of factors. See &#8220;Cautionary Note Regarding Forward-Looking Statements.&#8221;</i></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="9" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><a id="P1PROCEEDS" name="P1_PROCEEDS" title="P1_PROCEEDS"></a>USE OF PROCEEDS</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">Unless otherwise indicated in the applicable prospectus supplement, we will use the net proceeds from the sale of securities offered by this prospectus for expenses primarily related to general corporate purposes, including to fund the clinical development of our lead drug candidate, CNM-Au8, including for conducting our on-going and planned clinical trials&nbsp;and expanded access protocols; potential future commercialization efforts&nbsp;and future regulatory activities including preparation of regulatory filings; additional early-stage research and development activities; and for business development activities, working capital and other general corporate purposes. Any specific allocation of the net proceeds of an offering of securities to a specific purpose will be determined at the time of such offering and will be described in the related supplement to this prospectus.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">The expected use of net proceeds represents our intentions based upon our present plans and business conditions. We cannot specify with certainty all of the particular uses for the net proceeds. Due to uncertainties inherent in the drug development process, it is difficult to estimate the exact amounts of the net proceeds that will be used for any particular purpose. We may use our existing cash and the future payments, if any, generated from any future collaboration agreements to fund our operations, either of which may alter the amount of net proceeds used for a particular purpose. In addition, the amount, allocation and timing of our actual expenditures will depend upon numerous factors, including the results of our research and development efforts, the timing and success of clinical trials, and the timing of regulatory submissions. Accordingly, we will have broad discretion in using these net proceeds.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">We intend to invest the net proceeds we receive that are not used as described above in a variety of capital preservation investments, including investment-grade, interest-bearing instruments and certificates of deposit or direct or guaranteed obligations of the U.S. government.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="10" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><a id="P1CAPITALSTOCK" name="P1_CAPITALSTOCK" title="P1_CAPITALSTOCK"></a>DESCRIPTION OF CAPITAL STOCK</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;"><i>The following is a summary of the rights and preferences of our capital stock. While we believe that the following description covers the material terms of our capital stock, the description may not contain all of the information that is important to you. We encourage you to read carefully this entire prospectus, any future related prospectus supplement and certificates of designation relating to the securities, as applicable, our amended and restated certificate of incorporation (the &#8220;certificate of incorporation&#8221;) and amended and restated bylaws (the &#8220;bylaws&#8221;) and the other documents we refer to for a more complete understanding of our capital stock. Copies of our certificate of incorporation and bylaws are incorporated by reference as exhibits to the registration statement of which this prospectus is a part. See &#8220;Where You Can Find More Information&#8221; and &#8220;Information Incorporated by Reference.&#8221;</i></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 0pt;"><b>General</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">We are governed by the certificate of incorporation, as amended and restated from time to time, and the Delaware General Corporation Law (&#8220;DGCL&#8221;), and the common law of the state of Delaware. The following summary of certain provisions of our securities does not purport to be complete and is subject to our amended and restated certificate of incorporation, as amended, our amended and restated bylaws and the provisions of the DGCL. Copies of our amended and restated certificate of incorporation, as amended, and our amended and restated bylaws are incorporated by reference as Exhibits 3.1, 3.2, 3.3 and 3.4, respectively, to this prospectus</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">Our amended and restated certificate of incorporation authorizes a total number of shares of all classes of stock of&nbsp;<a data-tblloc="27x1" data-tblname="618876" data-tblv="16" id="led618876F202410201732138375492">601,000,000</a>&nbsp;shares, consisting of (i)&nbsp;<a data-tblloc="25x1" data-tblname="618876" data-tblv="16" id="led618876F202410201732138382814">600,000,000</a>&nbsp;shares of common stock, par value&nbsp;<a data-tblloc="25x2" data-tblname="618876" data-tblv="16" id="led618876F202410201732138361169">$0.0001</a>&nbsp;per share, and (ii)&nbsp;<a data-tblloc="26x1" data-tblname="618876" data-tblv="16" id="led618876F202410201732138388566">1,000,000</a>&nbsp;shares of preferred stock, par value&nbsp;<a data-tblloc="26x2" data-tblname="618876" data-tblv="16" id="led618876F202410201732138367716">$0.0001</a>&nbsp;per share.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 0pt;"><b>Common Stock</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">Our common stock is listed on Nasdaq under the symbol &#8220;CLNN.&#8221; The holders of our common stock are entitled to one vote for each share held on all matters to be voted on by stockholders and do not have cumulative voting rights. The holders of our common stock are entitled to receive dividends, if and when declared by our Board of Directors (the &#8220;Board&#8221;) out of funds legally available therefor. In the event of a liquidation, dissolution, or winding up of the Company, our stockholders are entitled to share ratably in all assets remaining available for distribution to them after payment of liabilities and after provision is made for each class of stock, if any, having preference over our common stock. Holders of our common stock have no preemptive or other subscription rights. Our Board is classified.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 0pt;"><b>Preferred Stock</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">Our preferred stock is currently undesignated and no shares of preferred stock are outstanding. The Board has the authority to issue shares of preferred stock from time to time on terms it may determine, to divide shares of preferred stock into one or more series and to fix the designations, preferences, privileges&nbsp;and restrictions of preferred stock, including dividend rights, conversion rights, voting rights, terms of redemption, liquidation preference, sinking fund terms&nbsp;and the number of shares constituting any series or the designation of any series to the fullest extent permitted by the DGCL. The issuance of preferred stock could have the effect of decreasing the trading price of common stock, restricting dividends on our capital stock, diluting the voting power of the common stock, impairing the liquidation rights of our capital stock or delaying or preventing a change in control of the Company. There is no restriction on the repurchase or redemption of shares by us while there is any arrearage in the payment of dividends or sinking fund installments.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 0pt;"><b>Warrants</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">As of the date of this prospectus, we had warrants outstanding that were exercisable into a total of <a data-tblloc="14x1" data-tblname="618876" data-tblv="16" id="led618876F202410201732145927267">7,242,876</a>&nbsp;shares of common stock, as outlined below.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="11" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 0pt;"><i><b>Public Warrants</b></i></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">The warrants originally issued by Tottenham are listed on Nasdaq under the symbol &#8220;CLNNW&#8221; (the &#8220;Public Warrants&#8221;). Each Public Warrant entitles the holder thereof to purchase one-fortieth (1/40) of one share of common stock at a price of&nbsp;<a data-tblloc="15x3" data-tblname="618876" data-tblv="16" id="led618876F202410211732214475433">$230.00</a> per full share. We will not issue fractional shares. As a result, a Public Warrant holder must exercise warrants in multiples of forty, at a price of&nbsp;<a data-tblloc="15x3" data-tblname="618876" data-tblv="16" id="led618876F202410211732214441278">$230.00</a> per full share, subject to adjustment, to validly exercise the warrants. The Public Warrants became exercisable upon the completion of the Reverse Recapitalization and will expire on December 30, 2025. As of the date of this prospectus, we had 4,815,000 Public Warrants outstanding exercisable into&nbsp;<a data-tblloc="15x1" data-tblname="618876" data-tblv="16" id="led618876F202410211732214493605">120,375</a> shares of common stock. The Public Warrants are currently exercisable.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">We may redeem the outstanding Public Warrants (excluding the private warrants that are part of the private units), in whole and not in part, at a price of $0.01 per warrant:</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">at any time while the warrants are exercisable;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 6pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">upon a minimum of 30 days&#8217; prior written notice of redemption;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 6pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">if, and only if, the last sales price of our common stock equals or exceeds $330.00 per share for any 20 trading days within a 30-trading day period ending three business days before we send the notice of redemption; and</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 6pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">if, and only if, (i) there is a current registration statement in effect with respect to our common stock underlying the warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption or (ii) the warrants may be exercised on a cashless basis as set forth in the warrant agreement and such cashless exercise is exempt from registration under the Securities Act.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">If the foregoing conditions are satisfied and we issue a notice of redemption, each warrant holder can exercise his, her or its warrant prior to the scheduled redemption date. However, the price of our common stock may fall below the $330.00 trigger price as well as the&nbsp;<a data-tblloc="15x3" data-tblname="618876" data-tblv="16" id="led618876F202410211732214454223">$230.00</a> exercise price per full share after the redemption notice is issued and not limit our ability to complete the redemption.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">If we call the Public Warrants for redemption as described above, our management will have the option to require all warrant holders that wish to exercise the warrants to do so on a &#8220;cashless&#8221; basis. In such event, each warrant holder would pay the exercise price by surrendering the whole warrant for that number of shares of common stock equal to the quotient obtained by dividing (x) the product of the number of shares of common stock underlying the warrants, multiplied by the difference between the exercise price of our warrants and the &#8220;fair market value&#8221; (as defined below) by (y) the fair market value. The &#8220;fair market value&#8221; means the average reported last sale price of our common stock for the ten trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the warrant holders. Whether we will exercise the option to require all warrant holders to exercise their warrants on a &#8220;cashless basis&#8221; will depend on a variety of factors, including the price of our common stock at the time the warrants are called for redemption, our cash needs at such time and concerns regarding dilutive share issuances.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 0pt;"><i><b>Option Warrants</b></i></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">In July 2021, Chardan Capital Markets, LLC (&#8220;Chardan&#8221;) exercised a unit purchase option originally issued in connection with Tottenham&#8217;s initial public offering in August 2018 for 11,000 units, each unit consisting of one and one-tenth (1/10) shares of common stock and twenty warrants to purchase one-fortieth (1/40) of one share of common stock at an exercise price of&nbsp;<a data-tblloc="16x3" data-tblname="618876" data-tblv="16" id="led618876F202410211732214526936">$230.00</a> per share. Chardan elected to perform a cashless or net exercise, which resulted in a net issuance of 49,166 warrants to purchase one-fortieth (1/40) of one share of common stock (the &#8220;Option Warrants&#8221;). The Option Warrants became exercisable upon issuance and are subject to the same expiration and redemption terms as the Public Warrants. As of the date of this prospectus, the Option Warrants are exercisable into&nbsp;<a data-tblloc="16x1" data-tblname="618876" data-tblv="16" id="led618876F202410211732214536442">1,229</a> shares of common stock.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="12" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 0pt;"><i><b>2023 Avenue Warrant</b></i></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">In June 2023, we issued a warrant (the &#8220;2023 Avenue Warrant&#8221;) in connection with an amendment to a loan agreement by and among the Company and our wholly owned subsidiary, Clene Nanomedicine, Inc., and Avenue and its affiliates. The 2023 Avenue Warrant became exercisable upon issuance and expires on June 30, 2028. Avenue may exercise the 2023 Avenue Warrant for cash or on a net or &#8220;cashless&#8221; basis. In the event of a change of control of the Company, the 2023 Avenue Warrant shall be automatically exchanged for the number of shares of common stock which remain exercisable thereunder immediately prior to the change of control transaction, for no payment or consideration from Avenue for such shares, and the 2023 Avenue Warrant shall be terminated. As of the date of this prospectus, the 2023 Avenue Warrant is exercisable into&nbsp;<a data-tblloc="17x1" data-tblname="618876" data-tblv="16" id="led618876F202410211732214550717">150,000</a> shares of common stock. Upon effectiveness of an amendment to the loan agreement, dated September 30, 2024, the 2023 Avenue Warrant was amended and restated to reflect an exercise price of&nbsp;<a data-tblloc="17x3" data-tblname="618876" data-tblv="16" id="led618876F202410211732214559439">$4.6014</a> per share. The other material terms of the 2023 Avenue Warrant remained effective as summarized herein.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 0pt;"><i><b>Tranche A Warrants &amp; Tranche B Warrants</b></i></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">In June 2023, pursuant to an underwritten public equity offering, we sold units each consisting of (i) one share of common stock, (ii) one warrant to purchase one share of common stock at an exercise price of&nbsp;<a data-tblloc="18x3" data-tblname="618876" data-tblv="16" id="led618876F202410211732214571449">$22.00</a> per share (the &#8220;Tranche A Warrants&#8221;), and (iii) one warrant to purchase one share of common stock at an exercise price of&nbsp;<a data-tblloc="19x3" data-tblname="618876" data-tblv="16" id="led618876F202410211732214579122">$30.00</a> per share (the &#8220;Tranche B Warrants&#8221;). The Tranche A Warrants were exercisable immediately and will expire on the earlier of (i) sixty (60) days following the date of our public announcement that the filing of a New Drug Application (&#8220;NDA&#8221;) for CNM-Au8 has been accepted by the U.S. Food and Drug Administration (&#8220;FDA&#8221;), or (ii) June 16, 2026. The Tranche B Warrants were exercisable immediately and will expire on the earlier of (i) sixty (60) days following the date of our public announcement that an NDA for CNM-Au8 has been approved by the FDA, or (ii) June 16, 2030. If we enter into or become party to a fundamental transaction (which generally includes a merger of the Company with or into another entity; the sale, lease, license, or transfer of all or substantially all of our assets; tender or exchange offers; or reclassification, reorganization, or recapitalization of our common stock), then (i) we or our successor entity shall purchase all outstanding Tranche A Warrants by paying the holders cash in an amount equal to the Black-Scholes value of the remaining unexercised portion of each Tranche A Warrant, and (ii) upon any subsequent exercise of a Tranche B Warrant, the holder shall be entitled to receive, at the option of the holder, the number of shares of common stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration receivable upon or as a result of such fundamental transaction by a holder of the number of shares of our common stock for which the warrant is exercisable immediately prior to such fundamental transaction. As of the date of this prospectus, the Tranche A Warrants and Tranche B Warrants are exercisable into <a data-tblloc="18x1" data-tblname="618876" data-tblv="16" id="led618876F202410211732214598572">2,500,000</a>&nbsp;and&nbsp;<a data-tblloc="19x1" data-tblname="618876" data-tblv="16" id="led618876F202410211732214605348">2,500,000</a> shares of common stock, respectively.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 0pt;"><i><b>2024 Pre-Funded Warrants</b></i></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">In October 2024, pursuant to a registered direct offering and a separate, concurrent private placement, we sold pre-funded warrants (the &#8220;2024 Pre-Funded Warrants&#8221;)&nbsp;with an exercise price of&nbsp;<a data-tblloc="20x3" data-tblname="618876" data-tblv="16" id="led618876F202410211732214617767">$0.001</a> per share of common stock. The 2024 Pre-Funded Warrants are currently exercisable and will expire when exercised in full. Additionally, the 2024 Pre-Funded Warrants may be exercised&nbsp;on a net or &#8220;cashless&#8221; basis.&nbsp;In the event of a fundamental transaction, as described in the 2024 Pre-Funded Warrants and generally including any merger or consolidation, or the sale, lease, license, assignment, transfer, or other conveyance or disposition of all or substantially all of our assets, or any purchase offer, tender offer or exchange offer is completed whereby holders of our common stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by holders of 50% or more of our outstanding common stock or voting power, any reclassification, reorganization or recapitalization of the common stock or&nbsp;any compulsory share exchange pursuant to which the common stock is effectively converted into or exchanged for other securities, cash or property, or consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) whereby any person or group acquires 50% or more of our outstanding common stock or voting power, then the holders of the 2024 Pre-Funded Warrants will be entitled to receive upon any subsequent exercise of the 2024 Pre-Funded Warrants, at the option of the holders, the number of shares of common stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration receivable as a result of such fundamental transaction. As of the date of this prospectus, the 2024 Pre-Funded Warrants are exercisable into&nbsp;<a data-tblloc="20x1" data-tblname="618876" data-tblv="16" id="led618876F202410211732214633246">424,358</a> shares of common stock.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="13" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">13</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 0pt;"><i><b>2024 Common Warrants</b></i></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">In October 2024, pursuant to a registered direct offering and&nbsp;separate, concurrent private placements, we sold warrants (the &#8220;2024 Common Warrants&#8221;)&nbsp;with an exercise price of&nbsp;<a data-tblloc="21x3" data-tblname="618876" data-tblv="16" id="led618876F202410211732214906189">$4.82</a> per share of common stock. The 2024 Common Warrants are currently exercisable and expire five (5) years from the issuance date of October 1, 2024. In the event of a fundamental transaction, as described in the 2024 Common Warrants and generally including any merger or consolidation, or the sale, lease, license, assignment, transfer, or other conveyance or disposition of all or substantially all of our assets, or any purchase offer, tender offer or exchange offer is completed whereby holders of our common stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by holders of 50% or more of our outstanding common stock or voting power, any reclassification, reorganization or recapitalization of the common stock or any compulsory share exchange pursuant to which the common stock is effectively converted into or exchanged for other securities, cash or property, or consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) whereby any person or group acquires 50% or more of our outstanding common stock or voting power, then holders of the 2024 Common Warrants will be entitled to receive upon any subsequent exercise of the 2024 Common Warrants, at the option of the holders, the number of shares of common stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration receivable as a result of such fundamental transaction. Notwithstanding anything to the contrary, in the event of a fundamental transaction, the Company or any successor entity shall, at the holder&#8217;s option, purchase the 2024 Common Warrants by paying to the holders the amount of cash equal to the Black Scholes Value (as defined in the 2024 Common Warrants) of the remaining unexercised portion of the 2024 Common Warrants on the date of the consummation of such fundamental transaction; provided, however, that, if the fundamental transaction is not within our control, including not approved by our Board of Directors, the holders shall only be entitled to receive from the Company or any successor the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of the 2024 Common Warrants, that is being offered and paid to the holders of our common stock in connection with the fundamental transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of our common stock are given the choice to receive from among alternative forms of consideration in connection with the fundamental transaction; provided, further, that if holders of our common stock are not offered or paid any consideration in such fundamental transaction, such holders of our common stock will be deemed to have received common stock of the successor in such fundamental transaction. As of the date of this prospectus, the 2024 Common Warrants are exercisable into&nbsp;<a data-tblloc="21x1" data-tblname="618876" data-tblv="16" id="led618876F202410211732214919631">1,546,914</a> shares of common stock.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 0pt;"><b>Stock Options</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">As of the date of this prospectus, we had outstanding stock options to purchase <a data-tblloc="7x1" data-tblname="618876" data-tblv="16" id="led618876F202410211732214370406">2,261,224</a>&nbsp;shares, with a weighted average exercise price of <a data-tblloc="8x1" data-tblname="618876" data-tblv="16" id="led618876F202410211732214376903">$24.58</a>&nbsp;per share.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 0pt;"><b>Restricted Stock Awards</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">As of the date of this prospectus, we had <a data-tblloc="9x1" data-tblname="618876" data-tblv="16" id="led618876F202410211732214383071">37,441</a>&nbsp;outstanding and unvested rights to restricted stock awards, which were subject to time-based and market-based vesting conditions.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 0pt;"><b>Contingent Earn-Outs</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">As of the date of this prospectus, we had outstanding and unvested earn-outs to issue <a data-tblloc="11x1" data-tblname="618876" data-tblv="16" id="led618876F202410211732214393825">329,628</a>&nbsp;shares, which were subject to market-based and performance-based vesting conditions.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 0pt;"><b>Senior Secured Convertible Promissory Notes</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">As of the date of this prospectus, we had outstanding senior secured convertible promissory notes&nbsp;(the &#8220;Notes&#8221;) in a principal amount totaling $10.0 million which we issued to Kensington Clene 2024 LLC, 4Life Research, LLC and La Scala Investments, LLC pursuant to a note purchase agreement. At the sole election of the holder of a Note, up to 65% of the outstanding principal balance of a Note may be converted into the number of shares of our common stock, equal to the outstanding principal balance elected by the holder to be converted divided by $5.668. Notwithstanding the foregoing, in the event that the holder of a Note declines to convert its pro rata share of outstanding principal balance, the remaining holders of the Notes may convert additional amounts, provided that no outstanding principal balance converted among all Notes exceeds $6.5 million. The Notes&nbsp;expire on the earlier of: (i) the date that is 18 months following the closing date of December 20, 2024, or (ii) a &#8220;Change in Control&#8221; as described below (the &#8220;Maturity Date&#8221;). Monthly principal repayments of $1,000,000 per month, made pro rata to the holders of the Notes, will commence on the 13-month anniversary of issuance and will continue until the Maturity Date, upon which date the remaining unpaid balance of principal together with any accrued and unpaid interest shall be due.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="14" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">14</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">A Change in Control means a merger or consolidation of us with or into any other entity in which our stockholders immediately prior to the merger or consolidation do not own more than 50% of the outstanding voting power (assuming conversion of all convertible securities and the exercise of all outstanding options and warrants) of the surviving entity or the sale, lease, licensing, transfer or other disposition of all or substantially all of our the assets; provided, however, that any new issuance of capital stock to one or more third parties for the sole purpose of providing new funding or solely in connection with a public offering of stock shall not constitute a Change in Control. In the event of a Change in Control or any bankruptcy, liquidation, or other restructuring process, the holder of a Note may, at its option, (i) convert up to 65% of the outstanding principal balance of the Note into common stock, (ii) receive a total return, paid in cash, equal to 115% of the outstanding principal balance of the Note, or (iii) any combination thereof, prior to such monetization event, before any security or claim junior to the Note shall receive any proceeds from such monetization event. Events of Default under the Notes include: (i) failure to deliver the conversion shares, (ii) default in the payment of the principal of, or any other amount owing in respect of, the Notes when they become due and payable and the continuance of such default for a period of ten business days after a written notice has been given to the Company; (iii) default in the performance or observance of any covenant or agreement of the Company in the Notes or the note purchase agreement, and the continuance of such default for a period of ten business days after a written notice has been given to the Company; (iv) the failure of the Company to maintain a minimum balance of $2.0 million in unrestricted cash; (v) the entry of a decree or order by a court adjudging the Company as bankrupt or insolvent; or approving as properly filed a petition seeking reorganization, arrangement, adjustment or composition of the Company, or appointing a receiver, liquidator, assignee, trustee or sequestrator of the Company or of any substantial part of its property, or ordering the winding-up or liquidation of its affairs, and the continuance of any such decree or order unstayed and in effect for a period of 60 calendar days; and (vi) the institution by the Company of proceedings to be adjudicated as bankrupt or insolvent, or the consent by it to the institution of bankruptcy or insolvency proceedings against it, or the filing by it of a petition or answer or consent seeking reorganization or relief, or the consent by it to the filing of any such petition or to the appointment of a receiver, liquidator, assignee, trustee or sequestrator of the Company or of any substantial part of its property, or the making by it of an assignment for the benefit of creditors.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 0pt;"><b>Convertible Notes Payable</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">As of the date of this prospectus, we had outstanding convertible notes payable under a loan agreement with the Maryland Department of Housing and Community Development (&#8220;DHCD&#8221;) which was convertible into&nbsp;<a data-tblloc="12x1" data-tblname="618876" data-tblv="16" id="led618876F202410211732214404786">62,500</a>&nbsp;shares of common stock at the discretion, but not the obligation, of DHCD at any time from December 8, 2023 through the maturity date of January 1, 2028.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 0pt;"><b>Indemnification Agreements</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">We have entered into indemnification agreements with each of our directors and executive officers. Each indemnification agreement provides for indemnification and advancement by us of certain expenses and costs relating to claims, suits or proceedings arising from service to us or, at our request, service to other entities, as officers or directors to the maximum extent permitted by applicable law.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 0pt;"><b>Dividends</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">We currently intend to retain all available funds and any future earnings to fund the growth and development of our business. We have never declared or paid any cash dividends on our capital stock. We do not intend to pay cash dividends to our stockholders in the foreseeable future. Our ability to declare dividends is limited by the terms of financing or other agreements that we have entered into. Future debt or other financing arrangements also may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. Investors should not purchase our common stock with the expectation of receiving cash dividends.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">Any future determination to declare dividends will be made at the discretion of our Board and will depend on our financial condition, operating results, capital requirements, general business conditions, and other factors that our Board may deem relevant.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 0pt;"><b>Transfer Agent and Registrar</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">The transfer agent and registrar for our common stock is Equiniti Trust Company, LLC. The transfer agent and registrar&#8217;s address is 48 Wall Street, Floor 23, New York, NY 10005.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="15" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">15</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><a id="P1DEBT" name="P1_DEBT" title="P1_DEBT"></a>DESCRIPTION OF DEBT SECURITIES</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;"><i>This section describes the general terms and provisions of our debt securities that we may issue from time to time. We may issue debt securities, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. While the terms we have summarized below will apply generally to any future debt securities we may offer under this prospectus, the applicable prospectus supplement will describe the specific terms of any debt securities offered through that prospectus supplement. The terms of any debt securities we offer under a prospectus supplement may differ from the terms we describe below, and to the extent the terms set forth in a prospectus supplement differ from the terms described below, the terms set forth in the prospectus supplement shall control. Unless the context requires otherwise, whenever we refer to the &#8220;indentures,&#8221; we are also referring to any supplemental indentures that specify the terms of a particular series of debt securities.</i></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;"><i>We will issue any senior debt securities under the senior indenture that we will enter into with the trustee named in the senior indenture. We will issue any subordinated debt securities under the subordinated indenture that we will enter into with the trustee named in the subordinated indenture. We have filed forms of these documents as exhibits to the registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC.</i></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;"><i>The indentures will be qualified under the Trust Indenture Act of 1939, as amended (the &#8220;Trust Indenture Act&#8221;). We use the term &#8220;trustee&#8221; to refer to either the trustee under the senior indenture or the trustee under the subordinated indenture, as applicable.</i></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;"><i>The following summaries of material provisions of the senior debt securities, the subordinated debt securities and the indentures are subject to, and qualified in their entirety by reference to, all of the provisions of the indenture applicable to a particular series of debt securities. We urge you to read the applicable prospectus supplement related to the debt securities that we may offer under this prospectus, as well as the complete applicable indenture that contains the terms of the debt securities. Except as we may otherwise indicate, the terms of the senior indenture and the subordinated indenture are identical.</i></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 0pt;"><b>General</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">We will describe in the applicable prospectus supplement the terms of the series of debt securities being offered, including:</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the title;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the principal amount being offered, and if a series, the total amount authorized and the total amount outstanding;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">any limit on the amount that may be issued;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">whether or not we will issue the series of debt securities in global form, and, if so, the terms and who the depository will be;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the maturity date;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">whether and under what circumstances, if any, we will pay additional amounts on any debt securities held by a person who is not a United States person for tax purposes, and whether we can redeem the debt securities if we have to pay such additional amounts;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the annual interest rate, which may be fixed or variable, or the method for determining the rate and the date interest will begin to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the terms of the subordination of any series of subordinated debt;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the place where payments will be payable;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">restrictions on transfer, sale or other assignment, if any;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="16" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">16</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our right, if any, to defer payment of interest and the maximum length of any such deferral period;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the date, if any, after which, the conditions upon which, and the price at which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those redemption provisions;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the date, if any, on which, and the price at which we are obligated, pursuant to any mandatory sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder&#8217;s option, to purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">whether the indenture will restrict our ability or the ability of our subsidiaries, if any at such time, to:</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9675;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">incur additional indebtedness;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9675;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">issue additional securities;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9675;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">create liens;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9675;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">pay dividends or make distributions in respect of our capital stock or the capital stock of our subsidiaries;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9675;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">redeem capital stock;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9675;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">place restrictions on our subsidiaries&#8217; ability to pay dividends, make distributions or transfer assets;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9675;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">make investments or other restricted payments;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9675;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">sell or otherwise dispose of assets;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9675;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">enter into sale-leaseback transactions;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9675;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">engage in transactions with stockholders or affiliates;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9675;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">issue or sell stock of our subsidiaries; or</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9675;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">effect a consolidation or merger;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">whether the indenture will require us to maintain any interest coverage, fixed charge, cash flow-based, asset-based or other financial ratios;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">a discussion of certain material U.S. federal income tax considerations applicable to the debt securities;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">information describing any book-entry features;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">provisions for a sinking fund purchase or other analogous fund, if any;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the applicability of the provisions in the indenture on discharge;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">whether the debt securities are to be offered at a price such that they will be deemed to be offered at an &#8220;original issue discount&#8221; as defined in paragraph (a) of Section 1273 of the Internal Revenue Code, as amended;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple thereof;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the currency of payment of debt securities if other than U.S. dollars and the manner of determining the equivalent amount in U.S. dollars; and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, including any additional events of default or covenants provided with respect to the debt securities, and any terms that may be required by us or advisable under applicable laws or regulations or advisable in connection with the marketing of the debt securities.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="17" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">17</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 0pt;"><b>Conversion or Exchange Rights</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">We will set forth in the applicable prospectus supplement the terms on which a series of debt securities may be convertible into or exchangeable for our common stock, our preferred stock or other securities (including securities of a third party). We will include provisions as to whether conversion or exchange is mandatory, at the option of the holder or at our option. We may include provisions pursuant to which the number of shares of our common stock, our preferred stock or other securities (including securities of a third-party) that the holders of the series of debt securities receive would be subject to adjustment.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 0pt;"><b>Consolidation, Merger or Sale</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the indentures will not contain any covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of all or substantially all of our assets. However, any successor to or acquirer of such assets must assume all of our obligations under the indentures or the debt securities, as appropriate. If the debt securities are convertible into or exchangeable for other securities of ours or securities of other entities, the person with whom we consolidate or merge or to whom we sell all of our property must make provisions for the conversion of the debt securities into securities that the holders of the debt securities would have received if they had converted the debt securities before the consolidation, merger or sale.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 0pt;"><b>Events of Default Under the Indenture</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the following are events of default under the indentures with respect to any series of debt securities that we may issue:</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">if we fail to pay interest when due and payable and our failure continues for 90 days and the time for payment has not been extended;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">if we fail to pay the principal, premium or sinking fund payment, if any, when due and payable at maturity, upon redemption or repurchase or otherwise, and the time for payment has not been extended;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">if we fail to observe or perform any other covenant contained in the debt securities or the indentures, other than a covenant specifically relating to another series of debt securities, and our failure continues for 90 days after we receive notice from the trustee or holders of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series; and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">if specified events of bankruptcy, insolvency or reorganization occur.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">We will describe in each applicable prospectus supplement any additional events of default relating to the relevant series of debt securities.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">If an event of default with respect to debt securities of any series occurs and is continuing, other than an event of default specified in the last bullet point above, the trustee or the holders of not less than a majority in aggregate principal amount of the outstanding debt securities of that series, by notice to us in writing, and to the trustee if notice is given by such holders, may declare the unpaid principal, premium, if any, and accrued interest, if any, due and payable immediately. If an event of default specified in the last bullet point above occurs with respect to us, the unpaid principal, premium, if any, and accrued interest, if any, of each issue of debt securities then outstanding shall be due and payable without any notice or other action on the part of the trustee or any holder.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">The holders of a majority in principal amount of the outstanding debt securities of an affected series may waive any default or event of default with respect to the series and its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default in accordance with the indenture. Any waiver shall cure the default or event of default.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="18" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">18</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">Subject to the terms of the indentures, if an event of default under an indenture shall occur and be continuing, the trustee will be under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have offered the trustee reasonable indemnity or security satisfactory to it against any loss, liability or expense. The holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series, provided that:</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the direction so given by the holder is not in conflict with any law or the applicable indenture; and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it in personal liability or might be unduly prejudicial to the holders not involved in the proceeding.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">A holder of the debt securities of any series will have the right to institute a proceeding under the indentures or to appoint a receiver or trustee, or to seek other remedies if:</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the holder has given written notice to the trustee of a continuing event of default with respect to that series;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have made written request, and such holders have offered reasonable indemnity to the trustee or security satisfactory to it against any loss, liability or expense or to be incurred in compliance with instituting the proceeding as trustee; and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal amount of the outstanding debt securities of that series other conflicting directions within 90 days after the notice, request and offer.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">These limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest on, the debt securities, or other defaults that may be specified in the applicable prospectus supplement.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">We will periodically file statements with the trustee regarding our compliance with specified covenants in the indentures.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 0pt;"><b>Modification of Indenture; Waiver</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">Subject to the terms of the indenture for any series of debt securities that we may issue, we and the trustee may change an indenture without the consent of any holders with respect to the following specific matters:</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">to fix any ambiguity, defect or inconsistency in the indenture;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">to comply with the provisions described above under &#8220;&#8212;Consolidation, Merger or Sale&#8221;;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust Indenture Act;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">to add to, delete from or revise the conditions, limitations, and restrictions on the authorized amount, terms, or purposes of issue, authentication and delivery of debt securities, as set forth in the indenture;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">to provide for the issuance of and establish the form and terms and conditions of the debt securities of any series as provided under &#8220;Description of Debt Securities&#8212;General,&#8221; to establish the form of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add to the rights of the holders of any series of debt securities;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">to evidence and provide for the acceptance of appointment hereunder by a successor trustee;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">to provide for uncertificated debt securities and to make all appropriate changes for such purpose;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="19" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">19</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">to add to our covenants such new covenants, restrictions, conditions or provisions for the benefit of the holders, to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of default or to surrender any right or power conferred to us in the indenture; or</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">to change anything that does not materially adversely affect the interests of any holder of debt securities of any series.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">In addition, under the indentures, the rights of holders of a series of debt securities may be changed by us and the trustee with the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, subject to the terms of the indenture for any series of debt securities that we may issue or as otherwise provided in the prospectus supplement applicable to a particular series of debt securities, we and the trustee may make the following changes only with the consent of each holder of any outstanding debt securities affected:</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">extending the stated maturity of the series of debt securities;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any premium payable upon the redemption or repurchase of any debt securities; or</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">reducing the percentage of debt securities, the holders of which are required to consent to any amendment, supplement, modification or waiver.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 0pt;"><b>Discharge</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">Each indenture provides that, subject to the terms of the indenture and any limitation otherwise provided in the prospectus supplement applicable to a particular series of debt securities, we can elect to be discharged from our obligations with respect to one or more series of debt securities, except for specified obligations, including obligations to:</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">register the transfer or exchange of debt securities of the series;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">replace stolen, lost or mutilated debt securities of the series;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">maintain paying agencies;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">hold monies for payment in trust;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">recover excess money held by the trustee;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">compensate and indemnify the trustee; and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">appoint any successor trustee.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">In order to exercise our rights to be discharged, we must deposit with the trustee money or government obligations sufficient to pay all the principal of, any premium, and interest on, the debt securities of the series on the dates payments are due.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 0pt;"><b>Form, Exchange and Transfer</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">We will issue the debt securities of each series only in fully registered form without coupons and, unless we otherwise specify in the applicable prospectus supplement, in denominations of $1,000 and any integral multiple thereof. The indentures provide that we may issue debt securities of a series in temporary or permanent global form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust Company or another depository named by us and identified in a prospectus supplement with respect to that series.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">At the option of the holder, subject to the terms of the indentures and the limitations applicable to global securities described in the applicable prospectus supplement, the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized denomination and of like tenor and aggregate principal amount.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="20" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">20</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">Subject to the terms of the indentures and the limitations applicable to global securities set forth in the applicable prospectus supplement, holders of the debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required by us or the security registrar, at the office of the security registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange, we will make no service charge for any registration of transfer or exchange, but we may require payment of any taxes or other governmental charges.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">We will name in the applicable prospectus supplement the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt securities. We may at any time designate additional transfer agents or rescind the designation of any transfer agent or approve a change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for the debt securities of each series. If we elect to redeem the debt securities of any series, we will not be required to:</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the opening of business 15 days before the day of mailing of a notice of redemption of any debt securities that may be selected for redemption and ending at the close of business on the day of the mailing; or</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except the unredeemed portion of any debt securities we are redeeming in part.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 0pt;"><b>Information Concerning the Trustee</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">The trustee, other than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those duties as are specifically set forth in the applicable indenture. Upon an event of default under an indenture, the trustee must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">Subject to this provision, the trustee is under no obligation to exercise any of the powers given it by the indentures at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that it might incur.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 0pt;"><b>Payment and Paying Agents</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">Unless we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">We will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents designated by us, except that unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail to the holder or by wire transfer to certain holders. Unless we otherwise indicate in the applicable prospectus supplement, we will designate the corporate trust office of the trustee as our sole paying agent for payments any other paying agents that we initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">All money we pay to a paying agent or the trustee for the payment of the principal of or any premium or interest on any debt securities that remains unclaimed at the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the Debt Security thereafter may look only to us for payment thereof.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 0pt;"><b>Governing Law</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">The indentures and the debt securities will be governed by and construed in accordance with the laws of the State of New York, except to the extent that the Trust Indenture Act is applicable.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="21" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">21</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 0pt;"><b>Ranking of Debt Securities</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">The subordinated debt securities will be subordinate and junior in priority of payment to certain of our other indebtedness to the extent described in a prospectus supplement. The subordinated indenture does not limit the amount of subordinated debt securities that we may issue. It also does not limit us from issuing any other secured or unsecured debt.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">The senior debt securities will rank equally in right of payment to all our other senior unsecured debt. The senior indenture does not limit the amount of senior debt securities that we may issue. It also does not limit us from issuing any other secured or unsecured debt.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="22" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">22</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><a id="P1WARRANTS" name="P1_WARRANTS" title="P1_WARRANTS"></a>DESCRIPTION OF WARRANTS</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">The following description, together with the additional information we may include in any applicable prospectus supplements, summarizes the material terms and provisions of the warrants that we may offer under this prospectus and the related warrant agreements and warrant certificates. While the terms summarized below will apply generally to any warrants that we may offer, we will describe the particular terms of any series of warrants in more detail in the applicable prospectus supplement. If we indicate in the prospectus supplement, the terms of any warrants offered under that prospectus supplement may differ from the terms described below. Specific warrant agreements will contain additional important terms and provisions and will be incorporated by reference as an exhibit to the registration statement, which includes this prospectus.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 0pt;"><b>General</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">We may issue warrants for the purchase of common stock, preferred stock or debt securities, in one or more series. We may issue warrants independently or together with common stock, preferred stock and/or debt securities, and the warrants may be attached to or separate from these securities.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">We plan to evidence each series of warrants by warrant certificates that we will issue under a separate warrant agreement. We will enter into the warrant agreement with a warrant agent. We will indicate the name and address of the warrant agent in the applicable prospectus supplement relating to a particular series of warrants.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">We will describe in the applicable prospectus supplement the terms of the series of warrants, including:</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the offering price and aggregate number of warrants offered;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the currency for which the warrants may be purchased;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each such security or each principal amount of such security;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">if applicable, the date on and after which the warrants and the related securities will be separately transferable;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the number of shares of common stock purchasable upon the exercise of one warrant and the price at which these shares may be purchased upon such exercise;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreement and the warrants;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the terms of any rights to redeem or call the warrants;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the periods during which, and places at which, the warrants are exercisable;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the manner of exercise;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the dates on which the right to exercise the warrants will commence and expire;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the manner in which the warrant agreement and warrants may be modified;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">if applicable, a discussion of certain material U.S. federal income tax considerations of holding or exercising the warrants; and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">any other specific terms, preferences, rights or limitations of or restrictions on the warrants.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="23" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">23</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><a id="P1UNITS" name="P1_UNITS" title="P1_UNITS"></a>DESCRIPTION OF UNITS</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b>General</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">We may issue units comprised of common stock, preferred stock, debt securities and warrants to purchase common stock, preferred stock or debt securities in any combination. We may issue units in such amounts and in as many distinct series as we wish. This section outlines certain provisions of the units that we may issue. If we issue units, they will be issued under one or more unit agreements to be entered into between us and a bank or other financial institution, as unit agent. The information described in this section may not be complete in all respects and is qualified entirely by reference to the unit agreement with respect to the units of any particular series. The specific terms of any series of units offered will be described in the applicable prospectus supplement. If so described in a particular supplement, the specific terms of any series of units may differ from the general description of terms presented below. We urge you to read any prospectus supplement related to any series of units we may offer, as well as the complete unit agreement and unit certificate that contain the terms of the units. If we issue units, forms of unit agreements and unit certificates relating to such units will be incorporated by reference as exhibits to the registration statement, which includes this prospectus.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">Each unit that we may issue will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included security. The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified date. The applicable prospectus supplement may describe:</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">any provisions of the governing unit agreement;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the price or prices at which such units will be issued;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the applicable U.S. federal income tax considerations relating to the units;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units; and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">any other terms of the units and of the securities comprising the units.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">The provisions described in this section, as well as those described under &#8220;Description of Capital Stock,&#8221; &#8220;Description of Debt Securities,&#8221; and &#8220;Description of Warrants&#8221; will apply to the securities included in each unit, to the extent relevant and as may be updated in any prospectus supplements. We may issue units in such amounts and in as many distinct series as we wish. This section summarizes terms of the units that apply generally to all series. Most of the financial and other specific terms of a particular series of units will be described in the applicable prospectus supplement.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="24" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">24</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><a id="P1DISTRIBUTION" name="P1_DISTRIBUTION" title="P1_DISTRIBUTION"></a>PLAN OF DISTRIBUTION</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">We may sell the securities from time to time pursuant to underwritten public offerings, &#8220;at the market offerings,&#8221; negotiated transactions, block trades, or a combination of these methods or any other method permitted pursuant to applicable law. We may sell the securities to or through one or more underwriters or dealers (acting as principal or agent), through agents, directly to one or more purchasers through a combination of&nbsp;any of those methods of sale or through any other means. We may distribute securities from time to time in one or more transactions:</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">at a fixed price or prices, which may be changed from time to time;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">at market prices prevailing at the time of sale;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">at prices related to such prevailing market prices; or</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">at negotiated prices.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">A prospectus supplement or supplements will describe the terms of the offering of the securities, including, to the extent applicable:</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the name or names of the underwriters, dealers, or agents, if any;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the purchase price of the securities or other consideration therefor, and the proceeds, if any, we will receive from the sale;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">any over-allotment or other options under which underwriters may purchase additional securities from us;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">any agency fees or underwriting discounts or concessions and other items constituting agents&#8217; or underwriters&#8217; compensation;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">any public offering price;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">any discounts or concessions allowed or reallowed or paid to dealers; and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">any securities exchange or market on which the securities may be listed.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b>At-the-Market Offerings</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">If we reach an agreement with an underwriter on a placement, including the number of shares of stock to be offered in the placement and any minimum price below which sales may not be made, such underwriter would agree to use its commercially reasonable efforts, consistent with its normal trading and sales practices, to try to sell such shares on such terms. Underwriters could make sales in privately negotiated transactions and/or any other method permitted by law, including sales deemed to be an &#8220;at-the-market&#8221; offering as defined in Rule 415 promulgated under the Securities Act, sales made directly on Nasdaq, the existing trading market for our stock, or sales made to or through a market maker other than on an exchange. The name of any such underwriter or agent involved in the offer and sale of our stock, the amounts underwritten, and the nature of its obligations to take our stock will be described in the applicable prospectus supplement.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b>Underwriters and Agents</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">Only underwriters named in the prospectus supplement will be underwriters of the securities offered by the prospectus supplement. Dealers and agents participating in the distribution of the securities may be deemed to be underwriters, and compensation received by them on resale of the securities may be deemed to be underwriting discounts. If such dealers or agents were deemed to be underwriters, they may be subject to statutory liabilities under the Securities Act.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="25" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">25</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">If underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time in one or more transactions at a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable underwriting agreement. We may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to certain conditions, the underwriters will be obligated to purchase all of the securities offered by the prospectus supplement, other than securities covered by any over-allotment option. If a dealer is used in the sale of securities, we or an underwriter will sell the securities to the dealer, as principal. The dealer may then resell the securities to the public at varying prices to be determined by the dealer at the time of resale. To the extent required, we will set forth in the prospectus supplement the name of the dealer and the terms of the transaction. Any public offering price and any discounts or concessions allowed or reallowed or paid to dealers may change from time to time.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">We may use underwriters, dealers or agents with whom we have a material relationship. We will describe in the prospectus supplement, naming the underwriter, dealer or agent, the nature of any such relationship.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">We may sell securities directly or through agents we designate from time to time. We may also designate agents to solicit offers to purchase the securities from time to time and may enter into arrangements for &#8220;at-the-market,&#8221; equity line or similar transactions. We will name any agent involved in the offering and sale of securities and we will describe any commissions payable to the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, the agent will act on a best-efforts basis for the period of its appointment.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">We may provide agents, underwriters and dealers with indemnification against civil liabilities, including liabilities under the Securities Act, or contribution with respect to payments that the agents, underwriters or dealers may make with respect to these liabilities. Agents, underwriters and dealers, or their affiliates, may engage in transactions with, or perform services for, us in the ordinary course of business.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">All securities we may offer, other than common stock, will be new issues of securities with no established trading market. Any underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee the liquidity of the trading markets for any securities.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">In order to facilitate the offering of the securities, any underwriters or agents, as the case may be, involved in the offering of such securities may engage in transactions that stabilize, maintain or otherwise affect the price of our securities. Specifically, the underwriters or agents, as the case may be, may over-allot in connection with the offering, creating a short position in our securities for their own account. In addition, to cover overallotments or to stabilize the price of our securities, the underwriters or agents, as the case may be, may bid for, and purchase, such securities in the open market. Finally, in any offering of securities through a syndicate of underwriters, the underwriting syndicate may reclaim selling concessions allotted to an underwriter or a broker-dealer for distributing such securities in the offering if the syndicate repurchases previously distributed securities in transactions to cover syndicate short positions, in stabilization transactions or otherwise. Any of these activities may stabilize or maintain the market price of the securities above independent market levels. The underwriters or agents, as the case may be, are not required to engage in these activities, and may end any of these activities at any time.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">Any underwriters that are qualified market makers on Nasdaq may engage in passive market making transactions in the common stock on Nasdaq in accordance with Regulation M under the Exchange Act, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the common stock. Passive market makers must comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security; if all independent bids are lowered below the passive market maker&#8217;s bid, however, the passive market maker&#8217;s bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the securities at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="26" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">26</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><a id="P1LEGAL" name="P1_LEGAL" title="P1_LEGAL"></a>LEGAL MATTERS</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">Unless otherwise indicated in the applicable prospectus supplement, the validity of the securities offered pursuant to this prospectus will be passed upon by Holland &amp; Knight LLP. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><a id="P1EXPERTS" name="P1_EXPERTS" title="P1_EXPERTS"></a>EXPERTS</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">The financial statements of Clene Inc. as of and for the years ended&nbsp;<a data-tblloc="7x1" data-tblname="618880" data-tblv="16" id="led618880F202410201732137485148">December 31, 2024</a>&nbsp;and&nbsp;<a data-tblloc="9x1" data-tblname="618880" data-tblv="16" id="led618880F20251281740701781471">2023</a>&nbsp;incorporated by reference in this prospectus have been audited by Deloitte &amp; Touche LLP, an independent registered public accounting firm, as stated in their report. Such financial statements are incorporated by reference in reliance upon the report of such firm given their authority as experts in auditing and accounting.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><a id="P1MOREINFO" name="P1_MOREINFO" title="P1_MOREINFO"></a>WHERE YOU CAN FIND MORE INFORMATION</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">We have filed with the SEC a Registration Statement on Form S-3, including exhibits, under the Securities Act, with respect to the securities offered pursuant to this prospectus. This prospectus is part of the Registration Statement, but does not contain all of the information included in the Registration Statement or the exhibits. For further information with respect to us and the securities offered by this prospectus, we refer you to the Registration Statement and its exhibits. Statements contained in this prospectus as to the contents of any contract or any other document referred to are not necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to the Registration Statement. Each of these statements is qualified in all respects by this reference.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">In addition, we file annual, quarterly, and current reports, proxy statements, and other information with the SEC. The SEC maintains an internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC, including our SEC filings, located at <i>https://www.sec.gov</i>. We also maintain a website at <i>https://clene.com</i>. The information contained in or accessible from our website is not incorporated into this prospectus, and you should not consider it part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. You may access, free of charge, our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="27" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">27</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><a id="P1INCORPORATED" name="P1_INCORPORATED" title="P1_INCORPORATED"></a>INFORMATION INCORPORATED BY REFERENCE</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">The SEC allows us to &#8220;incorporate by reference&#8221; information into this prospectus, which means that we can disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is deemed to be part of this prospectus, and subsequent information that we file with the SEC will automatically update and supersede that information. Any statement contained in this prospectus or a previously filed document incorporated by reference will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus or a subsequently filed document incorporated by reference modifies or replaces that statement.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">This prospectus and any accompanying prospectus supplement incorporate by reference the documents set forth below that have previously been filed with the SEC:</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our Annual Report on <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001822791/000143774925008956/clnn20241231_10k.htm" style="-sec-extract:exhibit;">Form 10-K</a> for the year ended <a data-tblloc="7x1" data-tblname="618880" data-tblv="16" id="led618880F202410201732137708202">December 31, 2024</a>, filed with the SEC on March 24, 2025;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto; font-size: 10pt;">our Current Reports on Form 8-K filed with the SEC on <a href="http://www.sec.gov/Archives/edgar/data/1822791/000143774925002265/clnn20241218_8k.htm" style="-sec-extract:exhibit;">January 30, 2025</a>&nbsp;and&nbsp;<a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001822791/000143774925007120/clnn20250311_8k.htm" style="-sec-extract:exhibit;">March 12, 2025</a>;</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 6pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the description of our common stock contained in the registration statement on <a href="http://www.sec.gov/Archives/edgar/data/1822791/000121390020045386/ea132360-8a12b_cleneinc.htm" style="-sec-extract:exhibit;">Form 8-A</a>, dated December 30, 2020, filed pursuant to Section 12(b) of the Exchange Act, as amended by <a href="http://www.sec.gov/Archives/edgar/data/1822791/000121390021007800/ea135056-8a12ba1_cleneinc.htm" style="-sec-extract:exhibit;">Amendment No. 1 to Form 8-A</a>, dated February 9, 2021.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">All reports and other documents we subsequently file pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination of this offering, including all such reports and other documents we may file with the SEC after the date of the initial registration statement and prior to the effectiveness of the registration statement, but excluding any information furnished to, rather than filed with, the SEC, will also be incorporated by reference into this prospectus and deemed to be part of this prospectus from the date of the filing of such reports and other documents.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">We will provide to each person, including any beneficial owner, to whom a prospectus is delivered, a copy of any or all of the information that has been incorporated by reference in the prospectus but not delivered with the prospectus. You may request a copy of any documents incorporated by reference in this prospectus, at no cost, by writing or telephoning us at:</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Clene Inc.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Attention: Investor Relations</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">6550 South Millrock Drive, Suite G50</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Salt Lake City, Utah 84121</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Telephone: 801-676-9695</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">Exhibits to the filings will not be sent, however, unless those exhibits have been specifically incorporated by reference in this prospectus or any accompanying prospectus supplement.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 21pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="28" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">28</div>
</div>
</div>

<div contenteditable="false" data-auto-pgnum="end">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 18pt; margin: 0pt; text-align: center;"><b><a data-tblloc="2x1" data-tblname="618883" data-tblv="16" id="led618883F202410201732137886427">$160,000,000</a></b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><img alt="clenelogo11percent.jpg" src="clenelogo11percent.jpg"></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 26pt; margin: 0pt; text-align: center;"><b>Clene Inc.</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 16pt; margin: 0pt; text-align: center;"><b>Common Stock</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 16pt; margin: 0pt; text-align: center;"><b>Preferred Stock</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 16pt; margin: 0pt; text-align: center;"><b>Debt Securities</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 16pt; margin: 0pt; text-align: center;"><b>Warrants</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 16pt; margin: 0pt; text-align: center;"><b>Units</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 16pt; margin: 0pt; text-align: center;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>PROSPECTUS</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; , 2025.</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><a id="PARTII" name="PARTII" title="PARTII"></a>PART II</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><a id="INFONOTREQUIRED" name="INFONOTREQUIRED" title="INFONOTREQUIRED"></a>INFORMATION NOT REQUIRED IN PROSPECTUS</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>ITEM 14. <i>Other Expenses of Issuance and Distribution</i>.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 21pt; text-align: justify;">The following table sets forth the expenses that will be paid by us in connection with the issuance and distribution of the securities being registered. In addition, we may incur additional expenses in the future in connection with the offering of our securities pursuant to this prospectus. If required, any such additional expenses will be disclosed in a prospectus supplement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 21pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 21pt; text-align: justify;">All amounts are estimates, except for the SEC registration fee.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 21pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" data-tbledgar="true" data-tblname="618886" data-tblv="16" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Amount to Be Paid</b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">SEC registration fee</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">24,496</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">FINRA filing fee</p>
			</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">24,500</p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accounting fees and expenses</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">*</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Legal fees and expenses</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">*</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Transfer agent fees and expenses</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">*</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Printing and miscellaneous fees and expenses</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">*</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">*</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>

<hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">*</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">Estimated expenses not presently known.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 21pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>ITEM 15. <i>Indemnification of Directors and Officers</i>.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 21pt; text-align: justify;">Section 145(a) of the DGCL provides, in general, that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation), because he or she is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding, if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 21pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 21pt; text-align: justify;">Section 145(b) of the DGCL provides, in general, that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor because the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#8217; fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification shall be made with respect to any claim, issue or matter as to which he or she shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, he or she is fairly and reasonably entitled to indemnity for such expenses that the Court of Chancery or other adjudicating court shall deem proper.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 21pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 21pt; text-align: justify;">Section 145(g) of the DGCL provides, in general, that a corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of his or her status as such, whether or not the corporation would have the power to indemnify the person against such liability under Section 145 of the DGCL.</p>

<div contenteditable="false" data-applyto="t" data-auto-pgnum="start" data-displaynum="1" data-fontname="'Times New Roman', Times, serif" data-fontsize="10pt" data-numstyle="a" data-prefix="II-" data-startnum="1" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 21pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="1" data-prefix="II-" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">II-1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 21pt; text-align: justify;">Our Certificate of Incorporation provides that no director of ours shall be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duty as a director, except for liability (1) for any breach of the director&#8217;s duty of loyalty to us or our stockholders, (2) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (3) in respect of unlawful dividend payments or stock redemptions or repurchases, or (4) for any transaction from which the director derived an improper personal benefit. In addition, our Certificate of Incorporation provides that if the DGCL is amended to authorize the further elimination or limitation of the liability of directors, then the liability of a director of ours shall be eliminated or limited to the fullest extent permitted by the DGCL, as so amended.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 21pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 21pt; text-align: justify;">Our Certificate of Incorporation further provides that any repeal or modification of such article by its stockholders or amendment to the DGCL will not adversely affect any right or protection existing at the time of such repeal or modification with respect to any acts or omissions occurring before such repeal or modification of a director serving at the time of such repeal or modification.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 21pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 21pt; text-align: justify;">Our Bylaws provide that we will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding whether civil, criminal, administrative or investigative (other than an action by or in the right of the Company) by reason of the fact that he or she is or was, or has agreed to become, the Company&#8217;s director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture or other enterprise (all such persons being referred to as an Indemnitee), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#8217; fees), judgments, fines, and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed to our best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful. Our Bylaws also provides that we will advance expenses to Indemnitees in connection with a legal proceeding, subject to limited exceptions.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 21pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 21pt; text-align: justify;">We have entered into indemnification agreements with each of our directors and executive officers. These agreements provide that we will indemnify each of our directors and such officers to the fullest extent permitted by law and our Certificate of Incorporation and our Bylaws.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 21pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 21pt; text-align: justify;">We will also maintain a general liability insurance policy, which will cover certain liabilities of directors and officers of ours arising out of claims based on acts or omissions in their capacities as directors or officers.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 21pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>ITEM 16. <i>Exhibits</i>.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 7%; font-size: 8pt; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);"><b>Exhibit Number</b></td>
			<td style="width: 1%; font-size: 8pt;">&nbsp;</td>
			<td style="width: 92%; font-size: 8pt; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);"><b>Exhibit Description</b></td>
		</tr>
		<tr>
			<td style="width: 7%; vertical-align: top;">1.1*</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 92%; text-align: justify; vertical-align: top;">Form of Underwriting Agreement.</td>
		</tr>
		<tr>
			<td style="width: 7%; vertical-align: top;">3.1</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 92%; text-align: justify; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1822791/000143774923013721/ex_517370.htm" style="-sec-extract:exhibit;">Fourth Amended and Restated Certificate of Incorporation of Clene Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed by the Registrant on May 11, 2023).</a></td>
		</tr>
		<tr>
			<td style="width: 7%; vertical-align: top;">3.2</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 92%; text-align: justify; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1822791/000143774924018759/ex_680309.htm" style="-sec-extract:exhibit;">Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of Clene Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed by the registrant on May 30, 2024).</a></td>
		</tr>
		<tr>
			<td style="width: 7%; vertical-align: top;">3.3</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 92%; text-align: justify; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1822791/000143774924022352/ex_692896.htm" style="-sec-extract:exhibit;">Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of Clene Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed by the registrant on July 9, 2024).</a></td>
		</tr>
		<tr>
			<td style="width: 7%; vertical-align: top;">3.4</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 92%; text-align: justify; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1822791/000121390021000487/ea132520ex3-2_cleneinc.htm" style="-sec-extract:exhibit;">Bylaws of Clene Inc. (incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K filed by the Registrant on January 5, 2021).</a></td>
		</tr>
		<tr>
			<td style="width: 7%; vertical-align: top;">4.1*</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 92%; text-align: justify; vertical-align: top;">Form of Preferred Stock Certificate.</td>
		</tr>
		<tr>
			<td style="width: 7%; vertical-align: top;">4.2*</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 92%; text-align: justify; vertical-align: top;">Form of Certificate of Designations.</td>
		</tr>
		<tr>
			<td style="width: 7%; vertical-align: top;">4.3*</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 92%; text-align: justify; vertical-align: top;">Form of Warrant Agreement and Warrant Certificate.</td>
		</tr>
		<tr>
			<td style="width: 7%; vertical-align: top;">4.4*</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 92%; text-align: justify; vertical-align: top;">Form of Unit Agreement and Unit Certificate.</td>
		</tr>
		<tr>
			<td style="width: 7%; vertical-align: top;">4.5</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 92%; text-align: justify; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1822791/000149315222009942/ex4-7.htm" style="-sec-extract:exhibit;">Form of Senior Indenture (incorporated by reference to Exhibit 4.7 to the Registration Statement on Form S-3, filed by the Registrant on April 14, 2022).</a></td>
		</tr>
		<tr>
			<td style="width: 7%; vertical-align: top;">4.6</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 92%; text-align: justify; vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1822791/000149315222009942/ex4-8.htm" style="-sec-extract:exhibit;">Form of Subordinated Indenture&nbsp;(incorporated by reference to Exhibit 4.8 to the Registration Statement on Form S-3, filed by the Registrant on April 14, 2022).</a></td>
		</tr>
		<tr>
			<td style="width: 7%; vertical-align: top;">5.1**</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 92%; text-align: justify; vertical-align: top;"><a href="ex_715566.htm" style="-sec-extract:exhibit;">Opinion of Holland &amp; Knight LLP.</a></td>
		</tr>
		<tr>
			<td style="width: 7%; vertical-align: top;">23.1**</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 92%; text-align: justify; vertical-align: top;"><a href="ex_715566.htm" style="-sec-extract:exhibit;">Consent of Holland &amp; Knight LLP (included as part of Exhibit 5.1).</a></td>
		</tr>
		<tr>
			<td style="width: 7%; vertical-align: top;">23.2**</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 92%; text-align: justify; vertical-align: top;"><a href="ex_715567.htm" style="-sec-extract:exhibit;">Consent of Deloitte &amp; Touche LLP.</a></td>
		</tr>
		<tr>
			<td style="width: 7%; vertical-align: top;">24.1</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 92%; text-align: justify; vertical-align: top;"><a href="#POWEROFATTORNEY" style="-sec-extract:exhibit;">Power of Attorney (included on signature page of the Registration Statement).</a></td>
		</tr>
		<tr>
			<td style="width: 7%; vertical-align: top;">107**</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 92%; text-align: justify; vertical-align: top;"><a href="ex_717302.htm" style="-sec-extract:exhibit;">Filing Fee Table.</a></td>
		</tr>

</table>

<hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">*</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">To be filed, if necessary, subsequent to the effectiveness of this Registration Statement by an amendment to this Registration Statement or a Current Report on Form 8-K.</p>
			</td>
		</tr>
		<tr>
			<td style="width: 27pt; font-size: 8pt;">**</td>
			<td style="width: auto; font-size: 8pt;">Filed herewith.</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="II-" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">II-2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;"><b>ITEM 17. <i>Undertakings</i>.</b></p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-indent: 21pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">The undersigned registrant hereby undertakes:</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 6pt; text-indent: 21pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(1)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 6pt; text-indent: 21pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 81pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(i)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">To include any prospectus required by Section 10(a)(3) of the Securities Act;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 6pt; text-indent: 21pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 81pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(ii)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Filing Fee Tables&#8221; or &#8220;Calculation of Registration Fee&#8221; table, as applicable, in the effective Registration Statement.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 8pt; text-indent: 21pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 81pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(iii)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 6pt; text-indent: 21pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">provided, however, that paragraphs (a)(1)(i), (ii), and (iii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of this Registration Statement.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 6pt; text-indent: 21pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(2)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 6pt; text-indent: 21pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(3)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 6pt; text-indent: 21pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(4)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">That, for the purpose of determining liability under the Securities Act to any purchaser:</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 6pt; text-indent: 21pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 81pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(i)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the Registration Statement as of the date the filed prospectus was deemed part of and included in the Registration Statement; and</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 6pt; text-indent: 21pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 81pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(ii)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i),(vii), or (x) for the purpose of providing the information required by Section 10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-indent: 21pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="II-" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">II-3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 27pt; font-size: 10pt;">(5)</td>
			<td style="width: auto;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this Registration Statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 6pt; text-indent: 21pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 81pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(i)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 6pt; text-indent: 21pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 81pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(ii)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 6pt; text-indent: 21pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 81pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(iii)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 6pt; text-indent: 21pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 81pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(iv)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 6pt; text-indent: 21pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt; font-size: 10pt;">(b)</td>
			<td style="width: auto;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant&#8217;s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 6pt; text-indent: 21pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt; font-size: 10pt;">(c)</td>
			<td style="width: auto;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 6pt; text-indent: 21pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(d)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The undersigned registrant hereby undertakes to file an application for the purpose of determining the eligibility of the trustee to act under subsection (a) of Section 310 of the Trust Indenture Act (the &#8220;Act&#8221;) in accordance with the rules and regulations prescribed by the SEC under section 305(b)(2) of the Act.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-indent: 21pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="II-" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">II-4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><a id="SIGNATURES" name="SIGNATURES" title="SIGNATURES"></a>SIGNATURES</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 21pt; text-align: justify;">Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3&nbsp;and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Salt Lake City, Utah, on <a data-tblloc="1x1" data-tblname="618880" data-tblv="16" id="led618880F202410201732137743407">March 24, 2025</a>.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 21pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td style="width: 50%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 3%;" valign="top" width="38%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 35%;" valign="top" width="38%">&nbsp;</td>
			<td style="width: 12%;" valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td colspan="2" rowspan="1" style="width: 3%;" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>CLENE INC.</b></p>
			</td>
			<td style="width: 12%;" valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 3%;" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" style="width: 35%;" valign="bottom" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 12%;" valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td align="left" style="text-align: left; width: 50%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="text-align: left; width: 3%;" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">By: </font></p>
			</td>
			<td align="left" nowrap="nowrap" style="border-bottom: 1px solid rgb(0, 0, 0); width: 35%;" valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">/s/ Robert Etherington</font></p>
			</td>
			<td style="width: 12%;" valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 3%;" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 35%;" valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">Robert Etherington</font></p>
			</td>
			<td style="width: 12%;" valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 3%;" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 35%;" valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">President and Chief Executive Officer</p>
			</td>
			<td style="width: 12%;" valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&nbsp;</p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 0pt; text-align: center;"><b><a id="POWEROFATTORNEY" name="POWEROFATTORNEY" title="POWEROFATTORNEY"></a>POWER OF ATTORNEY</b></p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 21pt; text-align: justify;">&nbsp;</p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 21pt; text-align: justify;">Each person whose signature appears below constitutes and appoints Robert Etherington attorney-in-fact, as his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in his name, place and stead, in any and all capacities, to sign any or all further amendments (including post-effective amendments) to this Registration Statement (and any additional registration statement related hereto permitted by Rule 462(b) promulgated under the Securities Act, (and all further amendments, including post-effective amendments, thereto)), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 21pt; text-align: justify;">&nbsp;</p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 21pt; text-align: justify;">Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.</p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 34%; text-align: center; border-bottom: 1px solid rgb(0, 0, 0); font-size: 8pt;"><b>Signature</b></td>
			<td style="width: 1%; font-size: 8pt;">&nbsp;</td>
			<td style="width: 36%; font-size: 8pt; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);"><b>Title</b></td>
			<td style="width: 1%; font-size: 8pt;">&nbsp;</td>
			<td style="width: 28%; font-size: 8pt; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);"><b>Date</b></td>
		</tr>
		<tr>
			<td style="width: 34%;">&nbsp;</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 36%;">&nbsp;</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 28%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 34%; text-align: center; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;">/s/ Robert Etherington</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 36%; text-align: center; vertical-align: bottom;">President, Chief Executive Officer, and Director</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 28%; text-align: center; vertical-align: bottom;"><a data-tblloc="1x1" data-tblname="618880" data-tblv="16" id="led618880F202410201732137769006">March 24, 2025</a></td>
		</tr>
		<tr>
			<td style="width: 34%; text-align: center; vertical-align: top;">Robert Etherington</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 36%; text-align: center; vertical-align: top;">(Principal Executive Officer)</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 28%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 34%;">&nbsp;</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 36%;">&nbsp;</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 28%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 34%; text-align: center; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;">/s/ Morgan R. Brown</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 36%; text-align: center; vertical-align: bottom;">Chief Financial Officer</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 28%; text-align: center; vertical-align: bottom;"><a data-tblloc="1x1" data-tblname="618880" data-tblv="16" id="led618880F202410201732137771607">March 24, 2025</a></td>
		</tr>
		<tr>
			<td style="width: 34%; text-align: center; vertical-align: top;">Morgan R. Brown</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 36%; text-align: center; vertical-align: top;">(Principal Financial and Accounting Officer)</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 28%; text-align: center;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 34%;">&nbsp;</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 36%;">&nbsp;</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 28%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 34%; text-align: center; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;">/s/&nbsp;David J. Matlin</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 36%; text-align: center; vertical-align: bottom;">Chairman of the Board</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 28%; text-align: center; vertical-align: bottom;"><a data-tblloc="1x1" data-tblname="618880" data-tblv="16" id="led618880F202410201732137774331">March 24, 2025</a></td>
		</tr>
		<tr>
			<td style="width: 34%; text-align: center; vertical-align: top;">David J. Matlin</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 36%; text-align: center;">&nbsp;</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 28%; text-align: center;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 34%;">&nbsp;</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 36%;">&nbsp;</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 28%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 34%; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);">/s/&nbsp;Arjun Desai</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 36%; text-align: center;">Director</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 28%; text-align: center;"><a data-tblloc="1x1" data-tblname="618880" data-tblv="16" id="led618880F202410201732137776907">March 24, 2025</a></td>
		</tr>
		<tr>
			<td style="width: 34%; text-align: center;">Arjun Desai</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 36%; text-align: center;">&nbsp;</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 28%; text-align: center;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 34%;">&nbsp;</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 36%;">&nbsp;</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 28%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 34%; text-align: center; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;">/s/&nbsp;Jonathon T. Gay</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 36%; text-align: center; vertical-align: bottom;">Director</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 28%; text-align: center; vertical-align: bottom;"><a data-tblloc="1x1" data-tblname="618880" data-tblv="16" id="led618880F202410201732137779525">March 24, 2025</a></td>
		</tr>
		<tr>
			<td style="width: 34%; text-align: center; vertical-align: top;">Jonathon T. Gay</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 36%; text-align: center;">&nbsp;</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 28%; text-align: center;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 34%;">&nbsp;</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 36%;">&nbsp;</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 28%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 34%; text-align: center; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;">/s/&nbsp;Shalom Jacobovitz</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 36%; text-align: center; vertical-align: bottom;">Director</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 28%; text-align: center; vertical-align: bottom;"><a data-tblloc="1x1" data-tblname="618880" data-tblv="16" id="led618880F202410201732137782337">March 24, 2025</a></td>
		</tr>
		<tr>
			<td style="width: 34%; text-align: center; vertical-align: top;">Shalom Jacobovitz</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 36%; text-align: center;">&nbsp;</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 28%; text-align: center;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 34%; text-align: center; vertical-align: top;">&nbsp;</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 36%; text-align: center;">&nbsp;</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 28%; text-align: center;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 34%; text-align: center; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0);">/s/&nbsp;Matthew Kiernan</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 36%; text-align: center;">Director</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 28%; text-align: center;"><a data-tblloc="1x1" data-tblname="618880" data-tblv="16" id="led618880F202410201732137785064">March 24, 2025</a></td>
		</tr>
		<tr>
			<td style="width: 34%; text-align: center; vertical-align: top;">Matthew Kiernan</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 36%; text-align: center;">&nbsp;</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 28%; text-align: center;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 34%;">&nbsp;</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 36%;">&nbsp;</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 28%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 34%; text-align: center; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;">/s/&nbsp;Vallerie V. McLaughlin</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 36%; text-align: center; vertical-align: bottom;">Director</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 28%; text-align: center; vertical-align: bottom;"><a data-tblloc="1x1" data-tblname="618880" data-tblv="16" id="led618880F202410201732137787841">March 24, 2025</a></td>
		</tr>
		<tr>
			<td style="width: 34%; text-align: center; vertical-align: top;">Vallerie V. McLaughlin</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 36%; text-align: center;">&nbsp;</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 28%; text-align: center;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 34%;">&nbsp;</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 36%;">&nbsp;</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 28%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 34%; text-align: center; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;">/s/&nbsp;Alison H. Mosca</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 36%; text-align: center; vertical-align: bottom;">Director</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 28%; text-align: center; vertical-align: bottom;"><a data-tblloc="1x1" data-tblname="618880" data-tblv="16" id="led618880F202410201732137791881">March 24, 2025</a></td>
		</tr>
		<tr>
			<td style="width: 34%; text-align: center; vertical-align: top;">Alison H. Mosca</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 36%; text-align: center;">&nbsp;</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 28%; text-align: center;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 34%;">&nbsp;</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 36%;">&nbsp;</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 28%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 34%; text-align: center; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;">/s/&nbsp;Reed Neil Wilcox</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 36%; text-align: center; vertical-align: bottom;">Director</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 28%; text-align: center; vertical-align: bottom;"><a data-tblloc="1x1" data-tblname="618880" data-tblv="16" id="led618880F202410201732137794475">March 24, 2025</a></td>
		</tr>
		<tr>
			<td style="width: 34%; text-align: center; vertical-align: top;">Reed Neil Wilcox</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 36%; text-align: center;">&nbsp;</td>
			<td style="width: 1%;">&nbsp;</td>
			<td style="width: 28%; text-align: center;">&nbsp;</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="II-" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">II-5</div>

<div contenteditable="false" data-auto-pgnum="end">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>ex_715566.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<html><head>
	<title>ex_715566.htm</title>
	<!-- Generated by ThunderDome Portal - 3/22/2025 5:49:19 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: right;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 5.1</b></font></p>

<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: justify;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<div style="text-align: justify;"><img alt="hklogo35px.jpg" src="hklogo35px.jpg"></div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; margin: 0pt; text-align: justify;"><font style="color:#002776;">200 South Orange Avenue, Suite 2600 | Orlando, FL 32801 | T 407.425.8500 | F 407.244.5288</font></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-variant: normal; margin: 0pt; text-align: justify;"><font style="color:#002776;">Holland &amp; Knight LLP | www.hklaw.com</font></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">March 24, 2025</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Clene Inc.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">6550 South Millrock Drive, Suite G50</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Salt Lake City, Utah 84121</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: -36pt; text-align: justify;">Ladies and Gentlemen:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We have acted as special counsel to Clene Inc., a Delaware corporation (the &#8220;Company&#8221;), with respect to the preparation of the shelf registration statement on Form S-3 (the &#8220;Registration Statement&#8221;) filed on or about the date hereof with the Securities and Exchange Commission (the &#8220;Commission&#8221;) in connection with the registration by the Company under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), of the offer and sale by the Company, pursuant to Rule 415 under the Securities Act, of the following securities, which may be issued from time to time at prices and on terms to be determined at the time of the offering:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(1)&nbsp;&nbsp; &nbsp;Debt securities of the Company, which may be either senior or subordinated and which may be issued in one or more series, consisting of notes or convertible notes (&#8220;Debt Securities&#8221;).</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(2)&nbsp;&nbsp; &nbsp;Shares of preferred stock, par value $0.0001 per share, of the Company, in one or more series (&#8220;Preferred Stock&#8221;).</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(3)&nbsp;&nbsp; &nbsp;Shares of common stock, par value $0.0001 per share, of the Company (&#8220;Common Stock&#8221;).</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(4)&nbsp;&nbsp; &nbsp;Warrants for the purchase of Common Stock, Preferred Stock or Debt Securities, or any combination of these securities (&#8220;Warrants&#8221;).</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(5)&nbsp;&nbsp; &nbsp;Units (the &#8220;Units&#8221; and, together with Debt Securities, Preferred Stock, Common Stock and Warrants, each a &#8220;Security&#8221; and together, the &#8220;Securities&#8221;) consisting of two or more of the types of Securities described above.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(6)&nbsp;&nbsp; &nbsp;Such indeterminate amount of Securities as may be issued in exchange for or upon conversion or exercise of, as the case may be, Securities.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We have also participated in the preparation of the Base Prospectus (the &#8220;Prospectus&#8221;) contained in the Registration Statement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In connection with the opinions expressed herein, we have examined, among other things, original counterparts or copies of original counterparts of the following documents:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(i)&nbsp;&nbsp; &nbsp;The organizational or governing documents of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(ii) &nbsp;&nbsp; &nbsp;The Registration Statement, including the Prospectus.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(iii) &nbsp;&nbsp; &nbsp;The form of Senior Indenture related to certain Debt Securities (the &#8220;Senior Indenture&#8221;).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(iv) &nbsp;&nbsp; &nbsp;The form of Subordinated Indenture related to certain Debt Securities (the &#8220;Subordinated Indenture,&#8221; and together with the Senior Indenture, the &#8220;Indentures&#8221;).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(v) &nbsp;&nbsp; &nbsp;The records of corporate proceedings of the Company that have occurred prior to the date hereof with respect to the Registration Statement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Clene Inc.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">March 24, 2025</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Page 2</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<hr class="hr-custom" style="height: 1px; color: #000000; background-color: #000000; width: 30%; border: none; margin: 3pt 0">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><div style="font-size: 10pt; text-indent: 36pt;">The Indentures, any warrant agreement relating to the Warrants (a &#8220;Warrant Agreement&#8221;), any agreement relating to the Units (a &#8220;Unit Agreement&#8221;) and any definitive purchase, underwriting or similar agreement entered into in connection with an issuance of Securities (a &#8220;Purchase Agreement&#8221;) are referred to herein collectively as the &#8220;Transaction Documents.&#8221; We have also examined originals or copies of such other records of the Company, certificates of public officials and of officers or other representatives of the Company and agreements and other documents as we have deemed necessary, subject to the assumptions set forth below, as a basis for the opinions expressed below.</div></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In rendering the opinions expressed below, we have assumed:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(i)&nbsp;&nbsp; &nbsp;The genuineness of all signatures (whether manual, electronic or otherwise) and, to the extent that a signature on a document is manifested by electronic or similar means, such signature has been executed or adopted by a signatory with an intent to authenticate and sign the document.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(ii)&nbsp;&nbsp; &nbsp;The authenticity of the originals of the documents submitted to us.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(iii)&nbsp;&nbsp; &nbsp;The conformity to authentic originals of any documents submitted to us as copies.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(iv)&nbsp;&nbsp; &nbsp;As to matters of fact, the truthfulness of the representations made or otherwise incorporated in the Registration Statement and the Transaction Documents and representations and statements made in certificates or web sites of public officials and officers or other representatives of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(v)&nbsp;&nbsp; &nbsp;That, at the time when any Security is issued:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(A)&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;(1) &nbsp;&nbsp; &nbsp;if such Security is a Debt Security, the applicable Indenture;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-indent: 36pt; text-align: justify;">(2)&nbsp;&nbsp; &nbsp;if such Security is a Warrant, a Warrant Agreement;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-indent: 36pt; text-align: justify;">(3)&nbsp;&nbsp; &nbsp;if such Security is a Unit, a Unit Agreement; and</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-indent: 36pt; text-align: justify;">(4)&nbsp;&nbsp; &nbsp;any applicable Purchase Agreement,</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 0pt; text-align: justify;">shall have been duly executed and delivered by the parties thereto and constitute valid, binding and enforceable obligations of each party thereto and such Security shall have been issued pursuant to the applicable foregoing agreements.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(B)&nbsp;&nbsp; &nbsp;The Company shall be an entity duly organized and validly existing under the laws of the jurisdiction of its organization.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(C)&nbsp;&nbsp; &nbsp;The Company shall have full power to execute, deliver and perform the applicable Transaction Documents to which it is a party and issue such Security, and shall have duly executed and delivered such applicable Transaction Documents.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(D)&nbsp;&nbsp; &nbsp;The execution, delivery and performance by the Company of the applicable Transaction Documents to which it is a party and the issuance of such Security (and, in the case of Units, of the Securities that are components of such Units) and any Security that may be issuable upon the exercise, conversion or exchange thereof, shall have been duly authorized by all necessary action and shall not contravene its certificate of incorporation or bylaws.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Clene Inc.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">March 24, 2025</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Page 3</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<hr class="hr-custom" style="height: 1px; color: #000000; background-color: #000000; width: 30%; border: none; margin: 3pt 0">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(E)&nbsp;&nbsp; &nbsp;The execution, delivery and performance by the Company of the applicable Transaction Documents to which it is a party and the issuance of such Security, will not:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-indent: 36pt; text-align: justify;">(1)&nbsp;&nbsp; &nbsp;violate any law, rule or regulation applicable to it (including without limitation federal and state securities laws), or</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-indent: 36pt; text-align: justify;">(2)&nbsp;&nbsp; &nbsp;result in any conflict with or breach of any agreement or document binding on it.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(F)&nbsp;&nbsp; &nbsp;No authorization, approval or other action by, and no notice to or filing with, any governmental authority or regulatory body (or, to the extent the same is required under any agreement or document binding on the Company or any third party) shall be required for the due execution, delivery or performance by the Company of any applicable Transaction Document to which it is a party or for the issuance of such Security by the Company, or, if any such authorization, approval, action, notice or filing is required, it shall have been duly obtained, taken, given or made and shall be in full force and effect.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(G)&nbsp;&nbsp; &nbsp;The Registration Statement, and any amendments thereto (including all necessary post-effective amendments), shall have become effective under the Securities Act.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(H)&nbsp;&nbsp; &nbsp;A supplement to the Prospectus (a &#8220;Prospectus Supplement&#8221;) shall have been prepared and filed with the Commission describing such Security.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(I)&nbsp;&nbsp; &nbsp;Such Security shall have been issued and sold in the manner stated in the Registration Statement and the appropriate Prospectus Supplement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(J)&nbsp;&nbsp; &nbsp;If such Security is Common Stock or Preferred Stock, the necessary number of applicable shares shall have been duly authorized and available for issuance pursuant to the Company&#8217;s Certificate of Incorporation.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(K)&nbsp;&nbsp; &nbsp;Any Security issuable upon conversion, exchange or exercise of such Security shall have been duly authorized, created and, if appropriate, reserved for issuance upon such conversion, exchange or exercise.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(L)&nbsp;&nbsp; &nbsp;If such Security is a series of Preferred Stock, or is convertible into or exchangeable or exercisable for a series of Preferred Stock, the Board of Directors of the Company (the &#8220;Board&#8221;) (or a committee thereof acting pursuant to authority delegated to it by the Board) shall have duly adopted a resolution establishing and designating such series and fixing and determining the preferences, limitations and relative rights of such series and a certificate of designation with respect to such series shall have been duly filed with the Secretary of State of the State of Delaware.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(M)&nbsp;&nbsp; &nbsp;The applicable Transaction Documents relating to such Security and, if such Security is a Debt Security, Warrant or Unit, such Security shall be governed by the laws of the State of New York, a New York State court, or a United States federal court sitting in the State of New York, would determine that Section 5-1401 of the New York General Obligations Law is applicable to the choice of New York law to govern such Transaction Documents and the issuance of such Security would involve at least the minimum amounts specified in such Section for it to be applicable.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(N)&nbsp;&nbsp; &nbsp;Such Security, if other than Common Stock or Preferred Stock, and if other than book entry or uncertificated, shall have been duly executed and delivered by the Company and, if applicable, duly authenticated or countersigned pursuant to the applicable Transaction Document.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(O)&nbsp;&nbsp; &nbsp;If such Security is other than Common Stock, the terms of such Security (and any Securities that are components thereof or issuable upon the exercise, conversion or exchange thereof) shall have been duly established in conformity with the applicable Transaction Document.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">(P)&nbsp;&nbsp; &nbsp;The Company shall not have been induced by fraud to enter into any Transaction Document.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Clene Inc.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">March 24, 2025</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Page 4</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<hr class="hr-custom" style="height: 1px; color: #000000; background-color: #000000; width: 30%; border: none; margin: 3pt 0">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We have not independently established the validity of the foregoing assumptions.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Based upon the foregoing and subject to the qualifications and limitations herein set forth herein, we are of the opinion that:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">1.&nbsp;&nbsp; &nbsp;With respect to any Debt Security being registered under the Registration Statement, when:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp; &nbsp;the applicable Indenture shall have been duly qualified under the Trust Indenture Act of 1939, as amended, and</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp; &nbsp;the consideration for such Debt Security provided for in the applicable Purchase Agreement shall have been paid,</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt; text-align: justify;">such Debt Security shall have been validly issued and shall constitute valid and binding obligations of the Company, enforceable against the Company in accordance with its terms.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">2.&nbsp;&nbsp; &nbsp;With respect to any share of Common Stock being registered under the Registration Statement, when:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp; &nbsp;a certificate representing such share shall have been duly executed, countersigned, registered and delivered (or, if such share is non-certificated, such share shall have been properly issued) either: (i) in accordance with the applicable Purchase Agreement or (ii) upon conversion, exchange or exercise of any other Security in accordance with the terms of such other Security or the agreement governing such other Security and providing for the conversion, exchange or exercise thereof, and</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp; &nbsp;the consideration therefor provided for in the applicable Purchase Agreement or in connection with such conversion, exchange or exercise, as applicable (in either case not less than the par value of such share of Common Stock), shall have been paid,</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt; text-align: justify;">such share shall have been validly issued, fully paid and non-assessable.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">3.&nbsp;&nbsp; &nbsp;With respect to any share of any series of Preferred Stock being registered under the Registration Statement, when:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp; &nbsp;a certificate representing such share shall have been duly executed, countersigned, registered and delivered (or, if such share is non-certificated, such share shall have been properly issued) either: (i) in accordance with the applicable Purchase Agreement or (ii) upon conversion, exchange or exercise of any other Security in accordance with the terms of such other Security or the agreement governing such other Security and providing for the conversion, exchange or exercise thereof, and</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp; &nbsp;the consideration therefor provided for in the applicable Purchase Agreement or in connection with such conversion, exchange or exercise, as applicable (in either case not less than the par value of such share of such series of Preferred Stock), shall have been paid,</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt; text-align: justify;">such share shall have been validly issued, fully paid, and non-assessable.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.&nbsp;&nbsp; &nbsp;With respect to any Warrant being registered under the Registration Statement, when:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp; &nbsp;the terms of such Warrant and of its issuance and sale shall have been duly established in conformity with the applicable Warrant Agreement and the applicable Purchase Agreement,</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp; &nbsp;the consideration provided for in the applicable Purchase Agreement shall have been duly paid, and</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Clene Inc.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">March 24, 2025</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Page 5</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<hr class="hr-custom" style="height: 1px; color: #000000; background-color: #000000; width: 30%; border: none; margin: 3pt 0">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(c)&nbsp;&nbsp; &nbsp;in the case of any Warrant exercisable for Preferred Stock or Common Stock, the exercise price payable in upon exercise thereof shall be at least equal to the aggregate par value of the Preferred Stock or Common Stock to be issued upon such exercise,</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt; text-align: justify;">such Warrant shall have been validly issued and shall constitute the valid and binding obligation of the Company, enforceable against the Company in accordance with its terms.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.&nbsp;&nbsp; &nbsp;With respect to any Unit being registered under the Registration Statement, when:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp; &nbsp;the terms of such Unit and of its issuance and sale shall have been duly established in conformity with the applicable Unit Agreement, and</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp; &nbsp;the consideration provided for in any applicable Purchase Agreement shall have been duly paid and, if Preferred Stock or Common Stock shall be components of such Unit, shall be in an amount at least equal to the aggregate par value of the Preferred Stock or Common Stock that are components of such Unit,</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt; text-align: justify;">such Unit shall have been validly issued and shall constitute the valid and binding obligation of the Company, enforceable against the Company in accordance with its terms.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The opinions set forth above are subject to the following qualifications and exceptions:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp; &nbsp;Our opinions are limited to the laws of the State of New York and the General Corporation Law of the State of Delaware, and we do not express any opinion herein concerning any other laws.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp; &nbsp;Our opinions are subject to bankruptcy, insolvency, fraudulent transfer, reorganization, receivership, moratorium or similar laws affecting the rights and remedies of creditors, stakeholders, or classes or groups of creditors or stakeholders generally.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">(c)&nbsp;&nbsp; &nbsp;Our opinions are subject to general principles of equity exercisable in the discretion of a court (including without limitation obligations and standards of good faith, fair dealing, materiality and reasonableness and defenses relating to unconscionability or to impracticability or impossibility of performance).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">(d)&nbsp;&nbsp; &nbsp;We express no opinion with respect to the enforceability of&nbsp;&nbsp; &nbsp;disclaimers, waivers, releases, indemnities, hold harmless provisions, exculpations, provisions for contribution and liquidated damages or payments that would constitute penalties, and other provisions, however expressed, altering or eliminating the rights, liabilities or remedies a party otherwise would have, or any provisions having the effect of modifying a statute of limitations.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">This opinion letter is rendered to you in connection with the transactions contemplated by the Registration Statement. This opinion letter has been prepared, and is to be understood, in accordance with customary practice of lawyers who regularly give and lawyers who regularly advise recipients regarding opinions of this kind, is limited to the matters expressly stated herein and is provided solely for purposes of complying with the requirements of the Securities Act, and no opinions may be inferred or implied beyond the matters expressly stated herein. The opinions expressed herein are rendered and speak only as of the date hereof and we specifically disclaim any responsibility to update such opinions subsequent to the date hereof or to advise you of subsequent developments affecting such opinions.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We consent to the filing of this opinion with the Commission as Exhibit 5.1 to the Registration Statement. We also consent to the reference of our firm under the caption &#8220;Legal Matters&#8221; in the Registration Statement. In giving this consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 and Section 11 of the Securities Act or the rules and regulations of the Commission promulgated thereunder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 55%; text-align: justify;">&nbsp;</td>
			<td style="width: 45%; text-align: justify;">Respectfully submitted,</td>
		</tr>
		<tr>
			<td style="width: 55%; text-align: justify;">&nbsp;</td>
			<td style="width: 45%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 55%; text-align: justify;">&nbsp;</td>
			<td style="width: 45%; text-align: justify;">HOLLAND &amp; KNIGHT LLP</td>
		</tr>
		<tr>
			<td style="width: 55%; text-align: justify;">&nbsp;</td>
			<td style="width: 45%; text-align: justify;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 55%; text-align: justify;">&nbsp;</td>
			<td style="width: 45%; text-align: justify;">/s/ Holland &amp; Knight LLP</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: justify;">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>3
<FILENAME>ex_715567.htm
<DESCRIPTION>EXHIBIT 23.2
<TEXT>
<html><head>
	<title>ex_715567.htm</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; padding:0in .1in;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 23.2</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: center;"><b>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&nbsp;</p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">We consent to the incorporation by reference in this Registration Statement on Form S-3 of our report dated March 24, 2025 relating to the financial statements of Clene Inc. appearing in the Annual Report on Form 10-K of Clene Inc. for the year ended December 31, 2024. We also consent to the reference to us under the heading <font style="font-family:'Times New Roman', Times, serif; font-size:10pt">&#8220;Experts&#8221;</font> in such Registration Statement.</p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&nbsp;</p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">/s/ Deloitte &amp; Touche LLP</p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Salt Lake City, UT</p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">March 24, 2025</p>

<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>4
<FILENAME>ex_717302.htm
<DESCRIPTION>EXHIBIT 107
<TEXT>
<html><head>
	<title>ex_717302.htm</title>
	<!-- Generated by ThunderDome Portal - 11/21/2024 7:31:47 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 107</b></font></p>

<p style="margin: 0px 0pt; text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Calculation of Filing Fee Tables</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 33%;">&nbsp;</td>
			<td style="width: 34%; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);"><a data-tblloc="3x0" data-tblname="618879" data-tblv="16" id="led618879F202410211732216615116">Form S-3</a></td>
			<td style="width: 33%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 33%;">&nbsp;</td>
			<td style="text-align: center; width: 34%;">(Form Type)</td>
			<td style="width: 33%;">&nbsp;</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 33%;">&nbsp;</td>
			<td style="text-align: center; border-bottom: 1px solid rgb(0, 0, 0); width: 34%;"><b>Clene Inc.</b></td>
			<td style="width: 33%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 33%;">&nbsp;</td>
			<td style="text-align: center; width: 34%;">(Exact Name of Registrant as Specified in its Charter)</td>
			<td style="width: 33%;">&nbsp;</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><u>Table 1: Newly Registered and Carry Forward Securities</u></p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%; border: 1px solid black;">

		<tr style="font-size: 8pt;">
			<td style="width: 11%; vertical-align: bottom; text-align: center; font-size: 8pt; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="width: 11%; vertical-align: bottom; text-align: center; font-size: 8pt; border-bottom: 1px solid black; border-right: 1px solid black;"><b>Security Type</b></td>
			<td style="width: 11%; vertical-align: bottom; text-align: center; font-size: 8pt; border-bottom: 1px solid black; border-right: 1px solid black;"><b>Security Class Title</b></td>
			<td style="width: 11%; vertical-align: bottom; text-align: center; font-size: 8pt; border-bottom: 1px solid black; border-right: 1px solid black;"><b>Fee Calculation or Carry Forward Rule</b></td>
			<td style="width: 11%; vertical-align: bottom; text-align: center; font-size: 8pt; border-bottom: 1px solid black; border-right: 1px solid black;"><b>Amount Registered</b></td>
			<td style="width: 11%; vertical-align: bottom; text-align: center; font-size: 8pt; border-bottom: 1px solid black; border-right: 1px solid black;"><b>Proposed Maximum Offering Price Per Unit</b></td>
			<td style="width: 11%; vertical-align: bottom; text-align: center; font-size: 8pt; border-bottom: 1px solid black; border-right: 1px solid black;"><b>Maximum Aggregate Offering Price</b></td>
			<td style="width: 11%; vertical-align: bottom; text-align: center; font-size: 8pt; border-bottom: 1px solid black; border-right: 1px solid black;"><b>Fee Rate</b></td>
			<td style="width: 11%; vertical-align: bottom; text-align: center; font-size: 8pt; border-bottom: 1px solid black;"><b>Amount of Registration Fee</b></td>
		</tr>
		<tr style="font-size: 8pt;">
			<td style="font-size: 8pt; vertical-align: bottom; border-bottom: 1px solid black; border-right: 1px solid black;"><a data-tblloc="12x0" data-tblname="618879" data-tblv="16" id="led618879F202410211732215990063">Fees to Be Paid</a></td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;"><a data-tblloc="12x1" data-tblname="618879" data-tblv="16" id="led618879F202410211732216017111">Equity</a></td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;"><a data-tblloc="12x2" data-tblname="618879" data-tblv="16" id="led618879F202410211732216050286">Common Stock, par value $0.0001 per share</a></td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black;">&nbsp;</td>
		</tr>
		<tr style="font-size: 8pt;">
			<td style="font-size: 8pt; vertical-align: bottom; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;"><a data-tblloc="13x1" data-tblname="618879" data-tblv="16" id="led618879F202410211732216022295">Equity</a></td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;"><a data-tblloc="13x2" data-tblname="618879" data-tblv="16" id="led618879F202410211732216057057">Preferred Stock, par value $0.0001 per share</a></td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black;">&nbsp;</td>
		</tr>
		<tr style="font-size: 8pt;">
			<td style="font-size: 8pt; vertical-align: bottom; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;"><a data-tblloc="14x1" data-tblname="618879" data-tblv="16" id="led618879F202410211732216027856">Debt</a></td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;"><a data-tblloc="14x2" data-tblname="618879" data-tblv="16" id="led618879F202410211732216062569">Debt Securities</a></td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black;">&nbsp;</td>
		</tr>
		<tr style="font-size: 8pt;">
			<td style="font-size: 8pt; vertical-align: bottom; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;"><a data-tblloc="15x1" data-tblname="618879" data-tblv="16" id="led618879F202410211732216033376">Other</a></td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;"><a data-tblloc="15x2" data-tblname="618879" data-tblv="16" id="led618879F202410211732216067731">Warrants</a></td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black;">&nbsp;</td>
		</tr>
		<tr style="font-size: 8pt;">
			<td style="font-size: 8pt; vertical-align: bottom; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;"><a data-tblloc="16x1" data-tblname="618879" data-tblv="16" id="led618879F202410211732216038953">Other</a></td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;"><a data-tblloc="16x2" data-tblname="618879" data-tblv="16" id="led618879F202410211732216072653">Units</a></td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black;">&nbsp;</td>
		</tr>
		<tr style="font-size: 8pt;">
			<td style="font-size: 8pt; vertical-align: bottom; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;"><a data-tblloc="17x1" data-tblname="618879" data-tblv="16" id="led618879F202410211732216043956">Unallocated (Universal Shelf)</a></td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;"><a data-tblloc="17x3" data-tblname="618879" data-tblv="16" id="led618879F202410211732216086279">457(o)</a></td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;"><a data-tblloc="17x4" data-tblname="618879" data-tblv="16" id="led618879F202410211732216096993">(1)</a></td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;"><a data-tblloc="17x5" data-tblname="618879" data-tblv="16" id="led618879F202410211732216101592">(2)</a></td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;"><a data-tblloc="17x6" data-tblname="618879" data-tblv="16" id="led618879F202410211732216107422">$160,000,000</a></td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;"><a data-tblloc="17x7" data-tblname="618879" data-tblv="16" id="led618879F202410211732216118217">$153.10 per $1,000,000</a></td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black;"><a data-tblloc="17x8" data-tblname="618879" data-tblv="16" id="led618879F202410211732216122884">$24,496.00</a></td>
		</tr>
		<tr style="font-size: 8pt;">
			<td style="font-size: 8pt; vertical-align: bottom; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td colspan="4" rowspan="1" style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;"><b>Total Offering Amounts</b></td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;"><a data-tblloc="18x3" data-tblname="618879" data-tblv="16" id="led618879F202410211732216112531"></a></td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black;"><a data-tblloc="18x5" data-tblname="618879" data-tblv="16" id="led618879F202410211732216126004"></a></td>
		</tr>
		<tr style="font-size: 8pt;">
			<td style="font-size: 8pt; vertical-align: bottom; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td colspan="4" rowspan="1" style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;"><b>Total Fees Previously Paid</b></td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black;"><a data-tblloc="19x5" data-tblname="618879" data-tblv="16" id="led618879F202410211732216129436"></a></td>
		</tr>
		<tr style="font-size: 8pt;">
			<td style="font-size: 8pt; vertical-align: bottom; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td colspan="4" rowspan="1" style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;"><b>Total Fee Offsets</b></td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-bottom: 1px solid black;"><a data-tblloc="20x5" data-tblname="618879" data-tblv="16" id="led618879F202410211732216134032"></a></td>
		</tr>
		<tr style="font-size: 8pt;">
			<td style="font-size: 8pt; vertical-align: bottom; border-right: 1px solid black;">&nbsp;</td>
			<td colspan="4" rowspan="1" style="font-size: 8pt; vertical-align: bottom; text-align: center; border-right: 1px solid black;"><b>Net Fee Due</b></td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center; border-right: 1px solid black;">&nbsp;</td>
			<td style="font-size: 8pt; vertical-align: bottom; text-align: center;"><a data-tblloc="21x5" data-tblname="618879" data-tblv="16" id="led618879F202410211732216137465"></a></td>
		</tr>

</table>

<hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt; font-size: 8pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">(1)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin: 0pt;">There are being registered hereunder, an indeterminate number or amount, as the case may be, of common stock, preferred stock, debt securities, warrants to purchase common stock, and units as permitted by General Instruction II.D, as may be offered by the registrant from time to time, which together shall have an aggregate initial offering price not to exceed <a data-tblloc="2x1" data-tblname="618883" data-tblv="16" id="led618883F202410211732217499028">$160,000,000</a>. Any securities registered hereunder may be sold separately or as units with other securities registered hereunder. The securities registered hereunder also include an indeterminate number of securities as may be issued upon conversion or exercise of or exchange for preferred stock or debt securities that provide for conversion or exchange, upon exercise of warrants, or pursuant to the anti-dilution provisions of any of such securities. In addition, pursuant to Rule 416 under the Securities Act of 1933, as amended, or the Securities Act, this registration statement also covers any additional securities that may be offered or issued in connection with any stock splits, stock dividends or similar transactions.</p>
			</td>
		</tr>
		<tr>
			<td style="width: 27pt; font-size: 8pt;">&nbsp;</td>
			<td style="width: 27pt; font-size: 8pt;">(2)</td>
			<td style="width: auto; font-size: 8pt;">Estimated solely for purposes of computing the registration fee. The proposed maximum offering price per unit and proposed maximum aggregate offering price for each type of security will be determined from time to time by the registrant in connection with the issuance by the registrant of the securities registered hereunder.</td>
		</tr>

</table>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>clenelogo11percent.jpg
<TEXT>
begin 644 clenelogo11percent.jpg
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M/F83PX$<V%VQ!+S/W=69 HI[TK3EAX5;<QN?H:"@\$Q@E8#<#8NC8MFX+^9
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M9-<%JO3Z<J&H]@A&$G:>N)E%/-!(8/IE_#8E5^(!?IS1C0[/&T*1;-+###6
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M\X9!(P&)R:GT5H^&TE'1Y*]KC[B6.3P9MD454K-;-Z)S77%L:P:WJ2%R;73
M1=A]ZJYT9#GLQ0MWU-9@AFZ6] /N^*+C]6Z#*9!J+J]?R2GI]%I'VUIP.@:U
MKDDI+/(ZA,@Y%3.9@F]20"X_2A(C,# [TE"2.OA8[K_9,\A2Q*Q!]U?FBW3>
M_.;0A0>BLNJ ^^+ #:=^I:<_I?MI<O!\L*%;Q_4)/2FR&/.##@V?,Y@3@XXP
M^&&,=&0YJ.?>;I8GHEE*N0!/$6,T!BYP=CP(C37(NH45TZ-I9>G(MF#RJ@M;
M7O(I Q@:QVQI8[((2%)J.B5I,D2/@=O5R(.G^OLO%"#G *KMQR)R-A\WN4)
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E"JI;C=S=+)N(I*"@4)0@^C]^(=+1VL-B@@    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>hklogo35px.jpg
<TEXT>
begin 644 hklogo35px.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M,]_?F7Q%=6B7H\.Z980>?<S10/\ NY+EU^6+S T8*MN4\5Q>O?&?XE?L0?\
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?)+1)>26R/J\N26&@UU2;]7N_4****\\[0HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>pipelinejan2025_22pct.jpg
<TEXT>
begin 644 pipelinejan2025_22pct.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M&<;XFC6E2C3C9>O;U/Z4/^'IG[./_1;/AO\ ^#N'_&C_ (>F?LX_]%L^&_\
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M?\0YPG_/V7X?Y!_K]B_^?<?Q_P S^E$?\%2_V<F.!\:OAR2> !K<//ZU?/\
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MR_\  E_\@'[_ /GC_P" O_Y,\<_X>1? ?_HJW@W_ ,#A1_P\B^ __15O!O\
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M;_X'"O9AJEL?^7B#_OX*7^T[?_GXA_[[%3S8;^27_@2_^0*MB/YX_P#@+_\
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M<*/^'D7P'_Z*MX-_\#A7MM%'/A?Y)?\ @2_^0*Y,3_/'_P !?_R1XE_P\B^
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M$8;'3P;C%\J3OJMTGM=]SF:***_H4_GT*;/_ *A_]TTZFS_ZA_\ =- 'J/\
MP63_ .2Q?!G_ +(QX:_]#O:^1*^N_P#@LG_R6+X,_P#9&/#7_H=[7R)7R&3_
M .YP]/U9]QFW^]S^7Y(****],\\**** "BBB@ HHHH **** "BBB@#1\'_\
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MGI4_UB_6B[ T=,TNV 7_ $>#I_SS%=!IFF6_R_Z/#_WP*QM,^ZOT_I6_IO\
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M_K5M!\K54M/N_C_6KB?=:N>1T0)J***S- HHHH **** "BBB@ HHHH ****
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MV_DI_=+_ .2#_B&F5?S3^^/_ ,B?B3%_P1I_:!N))4C\+:,[0-LD4:_:$HV
MV#\_!VLI^A%/_P"'+_[0W_0IZ3_X/K3_ .+K]I=*2&VU'4I(1-))<7"R3KN0
M^4_DQJ%X/'RJIP>?FST(J]]J;_GA-_X[_C0_$[-?Y(?=+_Y(F/AKE;6LI_\
M@4?_ )$_$S_AR_\ M#?]"GI/_@^M/_BZ/^'+_P"T-_T*>D_^#ZT_^+K]L_M3
M?\\)O_'?\:/M3?\ /";_ ,=_QH_XB=FW\E/[I?\ R17_ !#3*OYI_?'_ .1/
MQ,_X<O\ [0W_ $*>D_\ @^M/_BZ/^'+_ .T-_P!"GI/_ (/K3_XNOVS^U-_S
MPF_\=_QH^U-_SPF_\=_QH_XB=FW\E/[I?_)!_P 0TRK^:?WQ_P#D3\3/^'+_
M .T-_P!"GI/_ (/K3_XNC_AR_P#M#?\ 0IZ3_P"#ZT_^+K]L_M3?\\)O_'?\
M:/M3?\\)O_'?\:/^(G9M_)3^Z7_R0?\ $-,J_FG]\?\ Y$_$S_AR_P#M#?\
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M^-82XXS![QA]S_\ DC:/!. CM*?WK_Y$_.FQ_P"">7Q6@V[M"L?E'_03@_\
MBJU+']@;XH6_WM%LAD ?\A*'_P"*K] OM3?\\)O_ !W_ !H^U-_SPF_\=_QK
MGEQAC7]F/W/_ #-X\(X*.TI?>O\ (^%+7]AOXDPD;M'LQ_W$(?\ XJM2S_8O
M^(D(^;2;3KG_ (_XO_BJ^U_M3?\ /";_ ,=_QH^U-_SPF_\ '?\ &L9<4XM[
MJ/W/_,VCPOA%UE]Z_P CX[L?V0?'L ^;2[7_ ,#HO\:U++]E/QO /FTVU_\
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M_P =_P : )J*A^U-_P \)O\ QW_&C[4W_/";_P =_P : )J*A^U-_P \)O\
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M7=GRIDEQU'79C/;.>>E5%VDGL34UBT7Q10.E%24%%%% !1110 4444 %%%%
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M#DEUL'E\:3<:MY<UEU7)I9M63;WNEV)I8S'RK*,J5H<NK>_-KHM7H]+-G?\
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M$\2;5S$)BVYY$66OJ_\ XAX?$G_15=#_ /"?E_\ DBC_ (AX?$G_ $570_\
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M_!D/\SZ0^U2?\^TWYI_\51]JD_Y]IOS3_P"*KYM/_!8C]FU?^:G67_@JO_\
MXQ33_P %COV:U_YJ=9_^"G4/_C%'U2O_ "/[F5_K/D__ $%TO_!D/\SZ4^U2
M?\^TWYI_\51]JD_Y]IOS3_XJOFP_\%B_V;58K_PLZRR#@_\ $JO_ /XQ2C_@
ML3^S:?\ FIUC_P""J_\ _C%'U2O_ "/[F'^L^3_]!=+_ ,&0_P SZ2^U2?\
M/M-^:?\ Q5'VJ3_GVF_-/_BJ^;Q_P6#_ &;V_P":FV7_ (*K_P#^,4Y?^"OW
M[.+?\U,LO_!7?_\ QBCZI7_D?W,G_6K)5OC*7_@R'^9]'?:I/^?:;\T_^*H^
MU2?\^TWYI_\ %5\YK_P5X_9S;_FI=E_X*[[_ .,5(O\ P5P_9W;_ )J59?\
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M -%'L_\ P67W_P 9H_X>Q_L]_P#11[/_ ,%E]_\ &:/J6(_Y]R^YA_K?D/\
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M $4>S_\ !9??_&:/J6(_Y]R^YA_K?D/_ $&T?_!D/_DCZ$^U2?\ /M-^:?\
MQ5'VJ3_GVF_-/_BJ^>_^'L?[/?\ T4>S_P#!9??_ !FC_A['^SW_ -%'L_\
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M]_\ 11[/_P %E]_\9H_X>Q_L]_\ 11[/_P %E]_\9H^I8C_GW+[F'^M^0_\
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M^?:;\T_^*KY[_P"'L?[/?_11[/\ \%E]_P#&:/\ A['^SW_T4>S_ /!9??\
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MR.Y=HM/T0R71V0331[5BMY7X$1WXC;'&< Y'T]-^SKXDG^]#\0__  EM0_\
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M'6/JLEZ'JWA'JM>G>%NJ_P"?6O,?"/4?2O3O"W\/^?6O'Q&Y^K9/T/2_"_\
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ME-=WI9<S6V\G9;+O>]K7\FGG&8-)SPS3[:N[Y8O?:*NVKR[6M>]OK#PW\?O
MOC/PQ<:WH_C3PGJVBV=TEC<:A9ZQ;SVL%P[JB0O*KE5D9W10I.274 9(K0@^
M*'ANYMUFC\0:')"VI-HP=;^(J;]7:-K3.[_7JZLIB^^&4C&0:^6?&?[*WQ"^
M,6M:YXFG\'^$_A_=3V&A:-#HFF:L+S^U5L]:M;Z2YN95ABC"P0PR1VZ!68B:
M;=LW*@@T?]@SQIX5\?:3X@TBZL+:WU/XIW_BKQ7I$LY>&\MO[7O;FQU&!ND=
MVMM+%!(F,21^6"0UNF[-Y7@.6[KV=]M';1/=:/JDUI>R=M;5_:V87]W#N2MO
M9QOJUM+5=&T];7:OHG]3Z-\9/"/B+QYJ'A73_%/AR^\3Z4GF7NCV^IPRW]FO
M'S20*QD0?,.64=1ZUTE?(_[,_P"S#\4O@Y\0_A[I-Q:^&[/PKX!AO+74]6MK
MBTG;Q:DL4^+ORGL3>P7T\[V\UP?M@B)A< 3;]P^N!TKR\RPM'#U5&A-3BU>Z
M=^K6MMFTKVU:3LW<]7+<56Q%-RKP<&G:S371/2^Z3;5]$VFTK6"BBBO//1"B
MBB@ HHHH _+7_@Y^_P"27_"'_L,ZA_Z3QU\'_ #_ ))'I/\ VV_]'25]X?\
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MVK6][[-=CY3N?^"9EY<C_D=K=>?^@.3_ .UZS[G_ ()6W5P?^1\MU_[@A/\
M[<5]>>=-_P \?_'Q1YTW_/'_ ,?%?G"S'$+[7X+_ "/JY<!Y'+>C_P"33_\
MDCXRN?\ @D?=W _Y*%;K_P!P$_\ R16==?\ !'"[N3_R4>W7/_4OG_Y)K[>\
MZ;_GC_X^*/.F_P">/_CXJO[4Q*^U^"_R.:7ASP]+>A_Y//\ ^2/@^[_X(HWE
MSG_BYMNN?^I</_R56==?\$,KRY!_XNG;K_W+)/\ [=U^@/G3?\\?_'Q1YTW_
M #Q_\?%5_:V+6TOP7^1SR\+>&9;X;_R>I_\ )GYUW7_!!&\NL_\ %V;5<_\
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M .3:_3'SIO\ GC_X^*/.F_YX_P#CXJO[8QG\_P""_P C*7A/PJ]\+_Y/4_\
MDS\R=._X-\[R>_O(6^+"1K:RJB.WA-L3@HK%A_IG0%BO&>5/T%[_ (AZ+K_H
ML$/_ (2A_P#DROT:TW5;J[U;4HI(1Y=K,B18RN08D8Y)X;ECR..W45>\Z;_G
MC_X^*J6=8Q?;_!?Y&,?"'A)ZO"_^3U._^,_-?_B'GNO^BP0_^$J?_DRC_B'G
MNO\ HL$/_A*G_P"3*_2CSIO^>/\ X^*/.F_YX_\ CXI?VUC?Y_P7^0_^(/\
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MCSIO^>/_ (^*/[:QO\_X+_(/^(/\)?\ 0)_Y4J?_ "9^:_\ Q#SW7_18(?\
MPE3_ /)E'_$//=?]%@A_\)4__)E?I1YTW_/'_P ?%'G3?\\?_'Q1_;6-_G_!
M?Y!_Q!_A+_H$_P#*E3_Y,_-?_B'GNO\ HL$/_A*G_P"3*/\ B'GNO^BP0_\
MA*G_ .3*_2CSIO\ GC_X^*/.F_YX_P#CXH_MK&_S_@O\@_X@_P )?] G_E2I
M_P#)GYK_ /$//=?]%@A_\)4__)E'_$//=?\ 18(?_"5/_P F5^E'G3?\\?\
MQ\4>=-_SQ_\ 'Q1_;6-_G_!?Y!_Q!_A+_H$_\J5/_DS\U_\ B'GNO^BP0_\
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MI[*C_P" S_\ DS]K/^'R/[.__0\7G_A/:E_\8H_X?(_L[_\ 0\7G_A/:E_\
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M%/\ X_1_Q#VZ9_T534/_  0I_P#'Z/[<P?\ -^#_ ,@_X@WQ9_T#+_P93_\
MDC\S:*_3+_B'MTS_ **IJ'_@A3_X_1_Q#VZ9_P!%4U#_ ,$*?_'Z/[<P?\WX
M/_(/^(-\6?\ 0,O_  93_P#DC\S:*_3+_B'MTS_HJFH?^"%/_C]'_$/;IG_1
M5-0_\$*?_'Z/[<P?\WX/_(/^(-\6?] R_P#!E/\ ^2/S-HK],O\ B'MTS_HJ
MFH?^"%/_ (_1_P 0]NF?]%4U#_P0I_\ 'Z/[<P?\WX/_ "#_ (@WQ9_T#+_P
M93_^2/S-HK],O^(>W3/^BJ:A_P""%/\ X_1_Q#VZ9_T534/_  0I_P#'Z/[<
MP?\ -^#_ ,@_X@WQ9_T#+_P93_\ DC\S:*_3+_B'MTS_ **IJ'_@A3_X_1_Q
M#VZ9_P!%4U#_ ,$*?_'Z/[<P?\WX/_(/^(-\6?\ 0,O_  93_P#DC\S:*_3+
M_B'MTS_HJFH?^"%/_C]'_$/;IG_15-0_\$*?_'Z/[<P?\WX/_(/^(-\6?] R
M_P#!E/\ ^2/S-HK],O\ B'MTS_HJFH?^"%/_ (_1_P 0]NF?]%4U#_P0I_\
M'Z/[<P?\WX/_ "#_ (@WQ9_T#+_P93_^2/S-HK],O^(>W3/^BJ:A_P""%/\
MX_1_Q#VZ9_T534/_  0I_P#'Z/[<P?\ -^#_ ,@_X@WQ9_T#+_P93_\ DC\S
M:*_3+_B'MTS_ **IJ'_@A3_X_536O^" ^CZ#9I/-\4M499+B&W 30(\[I94B
M4\W X#."?8'KTHCG6#;LI?@_\B7X.\6)7>&7_@RG_P#)'YL45^F0_P"#>[3#
M_P U4U#_ ,$*?_'Z/^(>W3/^BJ:A_P""%/\ X_1_;F#_ )OP?^17_$&^+/\
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M17Z9?\0]NF?]%4U#_P $*?\ Q^C_ (A[=,_Z*IJ'_@A3_P"/T?VY@_YOP?\
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M-&^ZO^?2FV'PH2PQ_IS-CUB_^O5[0=.CN+N^A223=I\XMW+* &)CCDR.>F)
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M1]1Q'_/N7W,G_7#(>N-H_P#@R'^9],>9<?\ /*'_ +^G_P")H\RX_P">4/\
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M /0=1_\ !L/_ )(^E/,N/^>4/_?T_P#Q-'F7'_/*'_OZ?_B:^:_^'Q'[.O\
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M^9>\RX_YY0_]_3_\31YEQ_SRA_[^G_XFI(Y5E'RTZH-B'S+C_GE#_P!_3_\
M$T>9<?\ /*'_ +^G_P")J:B@"'S+C_GE#_W]/_Q-'F7'_/*'_OZ?_B:FHH A
M\RX_YY0_]_3_ /$T>9<?\\H?^_I_^)J:B@"'S+C_ )Y0_P#?T_\ Q-'F7'_/
M*'_OZ?\ XFIJ* (?,N/^>4/_ ']/_P 31YEQ_P \H?\ OZ?_ (FIJ* (?,N/
M^>4/_?T__$T>9<?\\H?^_I_^)J:B@"'S+C_GE#_W]/\ \31YEQ_SRA_[^G_X
MFIJ* (?,N/\ GE#_ -_3_P#$T>9<?\\H?^_I_P#B:FHH A\RX_YY0_\ ?T__
M !-'F7'_ #RA_P"_I_\ B:FHH _+/_@YY,A^%WPAWJJG^V=0^ZV[_EWC]A7P
MC\ /^21Z3_VV_P#1TE?>'_!S]_R2_P"$/_89U#_TGCKX/^ '_)(])_[;?^CI
M*_8<A_Y$%'_%+\Y'Y-GW_(ZJ^B_*)S-;G@+X9>)OBMJTUAX5\-^(/$]];PFX
MFMM(TZ:^FBC! WLL2L0N2!D\9('4@5AU]E?\$X/B+;Q_LW?$[P3H/Q3\/_!G
MXBZMJVGZI:>(-7ECMXKNQAP)(%DD(&Z,B1]O4B4C[I<K^EYQCJF$PSK4XW=T
MM;V2;2;=DW9+5V1^993@Z>*Q*HU)65F]+7=DVDKM*[V5V?,MS^SSX^LOA5_P
MG,W@WQ)#X/$AB.KO82+:J0_EY+8X7?\ )O("[OESGBN,F.8'_P!TU^M/QZ^-
M.GZW'\6/BH_QF\-^)/@OXF^'5WX8TGPM%J,@GN-88>6%6S*A5=F$G[S[Y6;Y
M@(XP]?DJXQ:MGKLY_*N'AW.*^80G.M!1LUM?2ZNXNZ7O1V=M-3NS_*:. G"-
M&;E=/>VMG925F_=ENKZGJ?\ P63_ .2Q?!G_ +(QX:_]#O:^1*^N_P#@LG_R
M6+X,_P#9&/#7_H=[7R)7%D_^YP]/U9[&;?[W/Y?D@HHHKTSSPHHHH **** "
MBBB@ HHHH **** -;P%_R/V@_P#83M?_ $<E?U:KW^M?RE> O^1^T'_L)VO_
M *.2OZM5[_6OROQ)^+#^DO\ VT_2O#[X:_\ V[^HM%%%?EY^C!1110 4444
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MVEO9+ SLJ8CCM;2"/:J!BN0LD;JLM?/.M:@-7UN\NU6:-;J>295FG,\BAF+
M-(>789Y8\L>>]71J5)?'&QRYM@<%AW_LE;VBN];6TLFG;H[MJS[%>BBBN@\4
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"]X>_X_OQ']:]5\&_P
M?2O*O#W_ !_?E_6O5?!O\'T%<]8][)OB/6?!WWXZ]6\(_<7Z"O*?!WWXZ]6\
M(_<7Z"O&K'ZQD^R/3?"/W5KT?PQTC^E><>$?NK7H_ACI']*\BKN?J&3]#T+P
M]T7\*[71.E<5X>Z+^%=KHG2O-GN?H67]#J+#_5U/4%A_JZGKFEN?11V"BBBD
M4%%%% !7GNA_M8?#?Q+\6)O ^G^,=%NO%4,\UI]ACFYDN(06GMT?[DD\2AC)
M$C&1 K%E&TX]")P*^7_!7[&7C30[3P?X%OM9\)R?#/X?^)4\2Z9>V]M,/$%\
M8;E[FWMI@?W,;+))B6Y1F:=%<>7&968>C@:.%J1F\1/E:V_&[V=[.RY=&[WN
MDF>;F%?%4Y0^KPYD]_PLMU:^OO:I6V=T>U>#_P!HWP/\0-(\,7^B^)-/U*S\
M92W$&C30,66^DMUD:=%./E:,0R[@V""C#J,5E^!?VQOA;\2AK;:)XZ\.WUOX
M=LWU*_N?M0CMHK-"P>[69\1R6RE3F=&:,8Y:OGCPA_P2PO- TCP3I_\ PDD&
MGZ4F@WVF^,;#3]RQWE]/I$^F+J=DQ0&.X,4P67< )!#"^ Z-YFW/^PU\2/B7
MX?U+1?%GC#0=+TN'PO'H%C#HKW]QIVHW5O<V4]G?S:9/(+:V6,66Q[:#/FI=
MS*TP&VO6GE^4*3Y:[MW[+F:VM[VB6UMT]FU'R*>89PXKFH)/MW]U-:W]W5O5
MWV:W2<O:O"/[9'PQ\=^&-2UC2?&.EWECHT]I;7Q =);5KN18K4O$RB0),[ 1
MOMV/R5) )&MIG[1_@?6;>26T\2:=<K!XD?PA+Y;%FAU='*-9N ,K(&'1L @J
MP.U@3XAX[_9$^(?QTU74O$OC'4O!.G^)FL]+T?3[/11<M9+:VVL6NI7$T\TB
M"2220VP6*,(%ARXWOYK,M*S_ ."=^IZ/X\T/Q1INLZ7I^IK\0K_Q-XB@B5S;
M:_I[ZO>ZA9!\KD7MLMUY:R# *221LS*L12'@<KY6W6:=]MTM$]TE?6ZNE:]E
M:UY%_7\VYM**:MOK%O5K;F=NCLW>UW>]HGN7A']J?X>>/?B;=^#=&\6:3J7B
M2R,RR6<$A;>T#!9TCDQLD>)B%D1&9HSPP4@UZ #FOF3]GS]D7XA?!WQAX!TR
M3Q3I<?@7X:VLVGVOV"]OX[CQ)9^1/%;PWMCO%DDT;3+*]THDDED@7 B5BH^F
MQP*\O,J.&I5%'"SYHVW\[OR5KJSMJU>S=TSU,LKXFK3<L5#EE?;RLO-WL[J^
MB=KI684445YYZ04444 %%%% 'Y:_\'/W_)+_ (0_]AG4/_2>.O@_X ?\DCTG
M_MM_Z.DK[P_X.?O^27_"'_L,ZA_Z3QU\'_ #_DD>D_\ ;;_T=)7[#D/_ "(*
M/^*7YR/R;/O^1U5]%^43F:[/]GC4K/1OC9X?NM0\"S?$RSBEE\SPQ$9 ^KY@
ME 4>7'(_R,1+PC<1=ADCC*[K]FI?B)#\9M)O_A78ZY>>-M+=I;)]+L!>RVN]
M&A9V5D>-4*R,I:0;1DG(QD?JN-_W>:;2]U[MQ6W62U2\UJMUJ?E.#O[>#2;U
M6R4GOTB]&_)Z/9Z'VOX&\(>!_CW\,?BFJ?L>GX:ZMX=\'WNJZ=JVJ2745L\R
M)@1B66UCVS!6,B !@WE,&*#YJ_.ICNM">N4SGUXK]'OC?X*_: \._LQZ]J7[
M1OQ]A\'Z+JUA<6]GX7LK>SDU'7;GR7*64DMK"@"NP =8VF4QE@Q4$D?G"_\
MQZMGKM-?-\)ZJM*,U*-U;EE4G%66MISWUU?+=+OV^CXIT=&,H.,K.]XPA)W>
MEXPVTVOJ^QZG_P %D_\ DL7P9_[(QX:_]#O:^1*^N_\ @LG_ ,EB^#/_ &1C
MPU_Z'>U\B4LG_P!SAZ?JSLS;_>Y_+\D%%%%>F>>%%%% !1110 4444 %%%%
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MN/\ GE%_W\/_ ,31YEQ_SRB_[^'_ .)H FHJ'S+C_GE%_P!_#_\ $T>9<?\
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MVZG_ )*]=?\ A,+_ /)5?I7YEQ_SRB_[^'_XFCS+C_GE%_W\/_Q-=7]L8O\
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M0 .Y(%?I!YEQ_P \HO\ OX?_ (FJ'B.Q;5=/CBF,4"+=6\P;S>K1S(ZKRO\
M$RA?QXYJHYUC&TG/\%_D3+PCX22;6#7_ ('4_P#DS\\O^(>^V_Z*U<_^$TO_
M ,DT?\0]]M_T5JY_\)I?_DFOT<$EQ_SRB_[^'_XFCS+C_GE%_P!_#_\ $U/]
MM8W^?\%_D5_Q"'A+_H$_\GJ?_)GYQ_\ $/=;_P#16KK_ ,)I?_DFC_B'NM_^
MBM77_A-+_P#)-?HYYEQ_SRB_[^'_ .)H\RX_YY1?]_#_ /$T?VUC?Y_P7^0?
M\0AX2_Z!/_)ZG_R9^<?_ !#W6_\ T5JZ_P#":7_Y)H_XA[K?_HK5U_X32_\
MR37Z.>9<?\\HO^_A_P#B:/,N/^>47_?P_P#Q-']M8W^?\%_D'_$(>$O^@3_R
M>I_\F?G'_P 0]UO_ -%:NO\ PFE_^2:/^(>ZW_Z*U=?^$TO_ ,DU^CGF7'_/
M*+_OX?\ XFCS+C_GE%_W\/\ \31_;6-_G_!?Y!_Q"'A+_H$_\GJ?_)GYQ_\
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M_P#$UC+,,1+>7X+_ "/6H\#9'2_AT+?]O3_^2/#])_8J32\8\22/C_IP _\
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M1YEQ_P \HO\ OX?_ (F@":BH?,N/^>47_?P__$T>9<?\\HO^_A_^)H _+O\
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M^+#^DO\ VT_2O#[X:_\ V[^HM%%%?EY^C!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!0T_2ULM9U"X$N]KQD9DQ_J]J!?UQFK]9^
MG:.;'6M0NMX87S1G;MQLVIMZ]ZT*J6_]=B8:+;O^84445)04444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5G^)-(&N:='"TOD^7=6]QN(SG
MRIDEV]1][9C/;.>>E:%9_B?1FUW38X5D6/R[NVN<D9R(IXY2/QV8SVS50=I)
MWL345XM6N: Z44"BI*"BBB@ HHHH **** ([J[CLK=YII$BAC4L[NP54 ZDD
M\"N8U+XV>&M)<"?4552VT/L;83Z XP?PKYZ_;N_:&72M?F\-QW]O8V>CQ0W-
M_)(QV^8Q#@$ \E8]K*IX+.,@X%>.Z%^U5H?Q#\(6>BVNU;C3R\S2EW&8PV.>
MK*,,![#KZCS<ES*&95,5/#Q;I823C5E9V3Y;VB[6;O:/+O=WT5N;XG.>,:&#
MQ/U2,HJ5M+]7>S5D]+=WV/T$T#Q-8>*+0S:?=1W,:G:VT_,AZX93RIP0<$ X
M-6KR\ATZTEN+B2.&"!#)))(P5(U R6)/  '.37QK\./C1:_"C7='U*SE9+"Z
ME6&_C8G:\)/+ =L E@!W&?XCGYY_X.'/VO-8TS7/#_P7T>\FLM*O--77O$1B
MDV_V@KRO';VK8_Y9J89)'4Y#%H>RD'T.%<1A^(<;+"X!M*+UYE9I6O=J_JK=
MUK8Z8<5T?J,\3->]"R:3T;>UGV?X6>Y]8>._^"SW[-W@#7YM-F^(T.J7%NY2
M1](TN\U&VR/[L\,31./='85CK_P71_9K?IXRUC_PFM1_^,U^-?A#X>:#I6@R
M7&K+=:MK#K!)'9KFWL;,%T9HIY2RL9FC;< @*HH;.YC^YU-*^'OASXA7U]!I
MMG<:?<^;(UCLN"D4Y,2,(I3("L*JBNXDR1NWB0A LE?HDN'\NA1J8J5'$.A3
M3<JMHQA96O)*5IN&OQJ+C9.7-RIR7!'.,XJ<JBZ*E/:'O.771V;5]-8WYEHF
MD]#]@5_X+G?LVM_S..L?^$WJ/_QFGC_@N1^S>W_,X:O_ .$WJ/\ \9K\8OAK
M\"=0^(WQOTGP/'?6.GW.L.?)O[I7-NL7DM,)B$#/M,:;@ ">1Q6KXN_9>\6>
M'Q=7VC:?>^-/#5OH5KXE.OZ%IMW-81:=<([QW$Q>)7MQB*4,)E0CR7/*C=7M
MT>#<BJJ+A5FU)*2=U9I[._+;7MOY'@U.,,[A>]*/NMIZ.Z:WTYKZ=]C]BA_P
M7#_9Q/\ S.&L?^$WJ'_QFG+_ ,%O/V<V_P"9OU?_ ,)S4/\ XS7XZZ;^RK\1
MKK1=8U"3P7XET^UT/0#XGG>^TRXMO.T\311&>+<@\Q1YH<D<"-)&SA335_9J
M^)$>M)IK?#WQTNI2:?\ VLMH=!NQ.;/<%-SLV;O)#,JE\;02 2#77#@/(Y?\
MOI?^!Q_^1.67'.=Q_P"74?\ P&7_ ,D?L</^"V_[.A_YF[5O_"<U#_XS3E_X
M+8_L[-T\7:M_X3NH?_&:_'_PC^S9XQ\0^//"_A^^T74O#,_C"![K2KC6K*>S
MM[N!(6E:9&9,NFQ<Y0'[R^HJCX3^%5]XJU#P?:P7%K')XR5FM=XD/V<+/+ V
M\*I9FS$Q"QAF;*@ L0M=$?#W(W_R]GM?XH^?]S^[+[CGEQ_G:M^[AV^&7E_>
M_O+[S]C_ /A]?^SO_P!#;J__ (3NH?\ QFC_ (?7_L[_ /0VZO\ ^$[J'_QF
MOQ<\3Z-;Z#J*QVFI6>L6=Q;PW4%U:YPZ2QJX5D/*2+DHZ'.'5L%EVLW7_$7]
MF#QM\*K2XGUK2;=8K2\ATZ4VFHVU]MNI);N'[/\ N)'S*DUA=1N@Y1HAG ="
MVDO#O(X\O/5FN;:\HIOY.%^IG'Q"SN5W&G!\N]HR:7S4O)GZZ_\ #Z_]G?\
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MG_P63_Y+%\&?^R,>&O\ T.]KY$KZ[_X+)_\ )8O@S_V1CPU_Z'>U\B5S9/\
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MO^_9H^W+_P \YO\ OV:X?_AJ[X6_]%*\ _\ A0VG_P <H_X:N^%O_12O /\
MX4-I_P#'*/J]7^5_<P]G/LSJ-/:XAUS4)9?M#6\WE^0N&.W"X;CMS^=:'VY?
M^><W_?LUYOI_[4_PY77-0:;XE> _LK>7]GSXBLR/N_-@>9D<^M:'_#5GPN_Z
M*3X!_P#"@M/_ (Y52P]:_P +Z='V(A3G;9]?S.X^W+_SSF_[]FC[<O\ SSF_
M[]FN(_X:J^%__12/ 7_A06G_ ,<H_P"&JOA?_P!%(\!?^%!:?_'*GZM6_E?W
M,T]G/LSM_MR_\\YO^_9H^W+_ ,\YO^_9KB/^&JOA?_T4CP%_X4%I_P#'*/\
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M.W^W+_SSF_[]FC[<O_/.;_OV:XC_ (:J^%__ $4CP%_X4%I_\<H_X:J^%_\
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ME7B5\>'])?\ MI^E>'_PU_\ MW_VX****_,#]&"BBB@ HHHH **** "BBB@
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MZ]I&DC3-1?3GBFT35;OS"(XY0X>VM94 VRJ"K$,&##! #-ZU^R]\#_A=XM^
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M8D2:QN(56"?$&(O*F:-:QIYQ7FE*-!V=M;NUK)W^&]OE?RZ$QQE1JZ@[?/\
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MY%244!<C^QP_\\8_^^11]CA_YXQ_]\BI** N1_8X?^>,?_?(H^QP_P#/&/\
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M\&:'-X%\/Z;JO@[QE+XGO_BC%?0M>^((6GEEEPBC[4;J\CD\BX2;$*(TFUY
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MY\+?_![=?_(E'_$-_P#M&?\ /Y\+O_![=?\ R)7[N?VA#_>_\=-']H0_WO\
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M31_K]FG]W[O^"']OXKR^[_@GX1_\0W_[1G_/Y\+?_![=?_(E'_$-_P#M&?\
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M- $V*,8J'^T(?[W_ (Z:/[0A_O?^.F@";%&*A_M"'^]_XZ:/[0A_O?\ CIH
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MI+_@H^/^+N_"_P#[(SX4_P#0M0KP'97OW_!1_P#Y*Y\+_P#LC7A3_P!"U"O
MZ_$_Z_ ^"\1O^2BQ/K'_ -(B-V4;*=10?$#=E&RG44 -V4;*=10 W91LIU%
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MUF54+9K$P8'EMX;K],5>KX=3_@NI\/?.?=X+\<!,#:P%H6;UR/.X_,Y]JT-
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M4N8[F+PWIOB36K'R([#2]8UFVL9;>!())OM#QE]0M SJK!/M,?+[)C'CZO\
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M 'Y?_1C5^BW_  <%_P#)._AG_P!A.]_]$QU^=/@W_D7H?]^7_P!&-7VO"_\
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ME& .SIRQ3E[R5KF&.P_#D*+="I.4U%V33LY6=F_=5K-KK9I:];R?$K]EO7/
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MTTZFS_ZA_P#=- 'TE_P4?_Y*Y\+_ /LC7A3_ -"U"O Z]\_X*/\ _)7/A?\
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MQIT?V_\ U'VJWV_>_P!;YR>5]WG_ %FSV]>,U4=T3+X6: Z44#I14E!1110
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M"G_H6H5X'7OG_!1__DKGPO\ ^R->%/\ T+4*\#K\3_X'Y'P7B-_R46)]8_\
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MFCZG7_D?W,/]:LE_Z#*7_@R'^9]#?V?#_=;_ +Z/^-']GP_W6_[Z/^-?/?\
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M?>?_ !FE]3Q'\DON?^0_];LB_P"@VC_X,A_\D?0']GP_W6_[Z/\ C1_9\/\
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M_P#10[#_ , +S_XU1_P]&^ __10[#_P O/\ XU1]1Q/_ #[E]S_R#_7+(/\
MH.H_^#8?_)'O/]GP_P!UO^^C_C1_9\/]UO\ OH_XUX-_P]&^ _\ T4.P_P#
M"\_^-4?\/1O@/_T4.P_\ +S_ .-4?4<3_P ^Y?<_\@_URR#_ *#J/_@V'_R1
M[S_9\/\ =;_OH_XT?V?#_=;_ +Z/^->#?\/1O@/_ -%#L/\ P O/_C5'_#T;
MX#_]%#L/_ "\_P#C5'U'$_\ /N7W/_(/]<L@_P"@ZC_X-A_\D>\_V?#_ '6_
M[Z/^-']GP_W6_P"^C_C7@W_#T;X#_P#10[#_ , +S_XU1_P]&^ __10[#_P
MO/\ XU1]1Q/_ #[E]S_R#_7+(/\ H.H_^#8?_)'O/]GP_P!UO^^C_C1_9\/]
MUO\ OH_XUX-_P]&^ _\ T4.P_P# "\_^-5/I?_!33X%:O?QV\?Q&T>.20X#3
MP7%O&/J\D:JH]R11]1Q"U=.7W/\ R*CQAD+=EC:-_P#K[#_Y(]R_L^'^ZW_?
M1_QH_L^'^ZW_ 'T?\:AT#Q%I_BO1K;4M+OK/4M/O$$MO=6LRS0SH>C(ZDJP/
MJ#BKE<NVC/H(R4DI1=TR'^SX?[K?]]'_ !H_L^'^ZW_?1_QJ:B@HA_L^'^ZW
M_?1_QH_L^'^ZW_?1_P :FHH A_L^'^ZW_?1_QH_L^'^ZW_?1_P :FHH A_L^
M'^ZW_?1_QH_L^'^ZW_?1_P :FHH A_L^'^ZW_?1_QJCI5C8M>ZEY+%YOM*_:
M1N/R2>3%@?\ ?ORS^-:E9^C6EK;:CJSV\WF37%TLETNX'RI/(B4+CM\BQM@_
MWL]"*I;,F6Z+7]GP_P!UO^^C_C1_9\/]UO\ OH_XU-14E$/]GP_W6_[Z/^-'
M]GP_W6_[Z/\ C4VZB@"'^SX?[K?]]'_&C^SX?[K?]]'_ !J:@-DT 0_V?#_=
M;_OH_P"-']GP_P!UO^^C_C4U&>: (?[/A_NM_P!]'_&C^SX?[K?]]'_&IJ*
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MJX6E+F>%_P#)ZG_R1^8B_P#!N[J"_P#-8[7_ ,)1O_DRE_XAWM0(Y^,5J?\
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M^>G_  X4OO\ HJUK_P"$RW_R71_PX4OO^BK6O_A,M_\ )=?HX**G^W,;_/\
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MB,14KS=6J[MVU]%9?@=&'P].A!4Z2LE?\7=_BPHHHK$V/SQ_X."_^2=_#/\
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M_P#?D_\ Q5'EW7_/:W_[\G_XJK%%?+G](%?R[K_GM;_]^3_\51Y=U_SVM_\
MOR?_ (JK%% %?R[K_GM;_P#?D_\ Q5'EW7_/:W_[\G_XJK%% %?R[K_GM;_]
M^3_\51Y=U_SVM_\ OR?_ (JK%% %?R[K_GM;_P#?D_\ Q5'EW7_/:W_[\G_X
MJK%% %?R[K_GM;_]^3_\51Y=U_SVM_\ OR?_ (JK%% %?R[K_GM;_P#?D_\
MQ5'EW7_/:W_[\G_XJK%% %?R[K_GM;_]^3_\51Y=U_SVM_\ OR?_ (JK%% %
M?R[K_GM;_P#?D_\ Q5'EW7_/:W_[\G_XJK%% %?R[K_GM;_]^3_\51Y=U_SV
MM_\ OR?_ (JK%% %?R[K_GM;_P#?D_\ Q5'EW7_/:W_[\G_XJK%% &3;:/>P
M>(;R\-Q;[+B&&-1L8X*&0GY<\??'.3GT&.;WEW7_ #VM_P#OR?\ XJJ]I8W$
M7BB^N&DS:S6\"1)O)VNIE+G;T&0R<]\>U:%5+<F.WWE?R[K_ )[6_P#WY/\
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M^3_\55BB@"OY=U_SVM_^_)_^*H\NZ_Y[6_\ WY/_ ,55BB@"OY=U_P ]K?\
M[\G_ .*H\NZ_Y[6__?D__%58HH K^7=?\]K?_OR?_BJ/+NO^>UO_ -^3_P#%
M58HH K^7=?\ /:W_ ._)_P#BJ/+NO^>UO_WY/_Q56** *_EW7_/:W_[\G_XJ
MCR[K_GM;_P#?D_\ Q56** *_EW7_ #VM_P#OR?\ XJJ.D:3?6.H:I+)<0,MY
M=+-&"K-M401)TR-OS(QP">N<\X&MFL[1+2ZMM2U=[AV:&XNUDM@7W;(_(A4@
M#^']XLAQ[D]ZJ.S_ *ZHF6Z_KHRSY=U_SVM_^_)_^*H\NZ_Y[6__ 'Y/_P 5
M5BBI**_EW7_/:W_[\G_XJCR[K_GM;_\ ?D__ !56** *_EW7_/:W_P"_)_\
MBJ/+NO\ GM;_ /?D_P#Q56** *_EW7_/:W_[\G_XJCR[K_GM;_\ ?D__ !56
M** *_EW7_/:W_P"_)_\ BJ/+NO\ GM;_ /?D_P#Q56** *_EW7_/:W_[\G_X
MJCR[K_GM;_\ ?D__ !56** *_EW7_/:W_P"_)_\ BJ/+NO\ GM;_ /?D_P#Q
M56** *_EW7_/:W_[\G_XJCR[K_GM;_\ ?D__ !56** *_EW7_/:W_P"_)_\
MBJ/+NO\ GM;_ /?D_P#Q56** *_EW7_/:W_[\G_XJCR[K_GM;_\ ?D__ !56
M** /SM_X.!5E7X=?#3S'C;_B9WOW4*_\L8_<U^=O@W_D7HO]^7_T8U?HM_P<
M%_\ )._AG_V$[W_T3'7YT^#?^1>A_P!^7_T8U?H_"_\ NB^?YG\\XO\ Y.#C
M?^O4?RIG!T445^\GQH4V?_4/_NFG4V?_ %#_ .Z: /I+_@H__P E<^%__9&O
M"G_H6H5X'7OG_!1__DKGPO\ ^R->%/\ T+4*\#K\3_X'Y'P7B-_R46)]8_\
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M17GGH!1110 4444 ?GC_ ,'!?_)._AG_ -A.]_\ 1,=?G3X-_P"1>A_WY?\
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M '_H3_C!_P""K3O_ ).HHH_L/!?R?B_\Q?VQC/Y_P7^0?\117P!_Z$_XP?\
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MYW@_XM>69!]GV:5I^[9M7._-]][?OZ<;=O?-%%4LCP7\GXO_ #)EG&,NO?\
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M@OY/Q?\ F']L8S^?\%_D'_$45\ ?^A/^,'_@JT[_ .3J/^(HKX _]"?\8/\
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!V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
